Archive for the ‘Crispr’ Category

INTRODUCTION Clustered regularly interspaced short palindromic repeats (CRISPR) are a family of DNA sequences, which constitute a primitive immune system that is responsible for protecting prokaryotic cells from phage infections.

New York, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions : Industry Trends and Global Forecasts, 2021-2030" - https://www.reportlinker.com/p06130494/?utm_source=GNW It was first described in 1987, however, its potential as a gene editing tool was not realized until 2012. Since then, the CRISPR revolution has not shown any signs of slowing down and has been responsible for significant advances in molecular biology and therapy development. Fundamentally, the CRISPR/Cas system involves specific palindromic DNA sequences which work in tandem with a family of caspase enzymes (Cas9, Cas12), in order to excise gene fragments with high precision. Compared to the other targeted nuclease-based systems, CRISPR is relatively faster, and cost-efficient; as a result, the demand for this gene editing tool is very high. The relatively recent discovery / development of novel accompanying nucleases, namely Cas12a, Cas13, Cas14 and dCas9, has significantly improved the precision of this technology. Presently, there are several companies using different variants of the CRISPR/Cas technology for basic research, and the development of gene editing solutions. However, the therapeutic use of this versatile genetic manipulation tool is only being investigated by a select few stakeholders in the pharmaceutical industry. The aforementioned scenario is attributed to the surrogate licensing model, which has granted exclusive control of the associated intellectual property (IP) to three leading players, namely Editas Medicine, CRISPR Therapeutics and Intellia Therapeutics, in the contemporary market.

Clinical trials of CRISPR based therapeutics are currently focused mainly on oncological and hematological disorders; however, several product candidates against certain neurological disorders and infectious diseases, specifically targeting recurrent conditions, are under investigation. Post 2014, the overall interest in this technology has grown exponentially, with several start-ups entering the market and 6 of the top 10 pharmaceutical companies restructuring their efforts in this direction. Over time, a substantial body of evidence has also been generated validating the therapeutic applications of this technology, which has, in turn, prompted the establishment of numerous strategic partnerships (focused on therapy development and clinical research) and has caused investors to put in significant capital into innovator companies involved in this domain, over the last two years alone. In fact, the three leading companies in this industry segment together have combined market capitalization of more than USD 10 billion, and have raised more than USD 2.8 billion in various funding rounds. Despite the possibly limitless potential of the CRISPR/Cas technology, further investigation, probing its safety and therapeutic efficacy in large diverse populations, is required. Key impediments to approval and other existing challenges that are being addressed by stakeholders, include off-target toxicity-related concerns and complexities related to the delivery of CRISPR components into target cells. Concerning delivery, innovators in this field have reported notable success using different types of platforms for facilitating the intracellular administration of CRISPR components; examples of successful delivery methods include electroporation, AAV vectors and lipid nanoparticles (LNPs). A few companies are also evaluating bacteriophages as a potential delivery system for such products. Promising clinical results, and ongoing technical developments, coupled to the growing interest of biopharmaceutical developers, are anticipated to push pipeline products to higher phases and on to commercialization. We believe that the market is likely to evolve at a commendable pace over the next decade.

SCOPE OF THE REPORT The CRISPR Based Therapeutics Market, 2021-2030 report features an extensive study of the current market landscape and future opportunity for the players involved in the development of CRISPR based therapeutics for the treatment of a variety of disease conditions. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes: A review of the CRISPR based therapeutics that are currently in different stages of development. It features a detailed analysis of pipeline molecules, based on several relevant parameters, such as target therapeutic area (autoimmune disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, muscular diseases, neurological disorders, oncological disorders, ophthalmic diseases and others), phase of development (discovery, preclinical and clinical), approach of therapy (ex vivo and in vivo), cell source (autologous and allogeneic), type of therapy (CAR-T therapy, HSC therapy, T cell therapy, Phage therapy and others), and the type of technology used. It also includes information on the completed, ongoing and planned clinical trials for CRISPR based therapeutics, sponsored by various industry players. Elaborate profiles of key players in this domain. Each company profile features a brief overview of the company, its financial information (if available), a brief description of its therapeutic candidates, recent developments, and an informed future outlook. An in-depth analysis of around 2,000 patents related to CRISPR technology that have been filed / granted, since 2015, highlighting the key trends associated with these patents, across type of patent, publication year and application year, regional applicability, IPCR symbols, emerging focus areas, inventor information, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation. An analysis of the partnerships that have been inked by various stakeholders engaged in the development of CRISPR based therapeutics, during the period 2014-2020, covering research and licensing agreements, R&D agreements, licensing agreements, licensing and manufacturing agreement, product development and manufacturing agreements, joint ventures and other types of partnership deals. An analysis of the investments made at various stages of development of the companies engaged in this field, covering instances of seed financing, venture capital financing, grants / awards, capital raised from IPOs and subsequent offerings. An analysis of the start-ups (established in the time period between 2013-2020 and have less than 200 employees) engaged in the development of CRISPR based therapeutics, based on several parameters, such as number of candidates in discovery, preclinical and clinical phase of development, therapeutic area, amount raised through funding, number of investors, type of funding, number of deals signed, and number of patents filed.

One of the key objectives of the report was to estimate the future growth potential of CRISPR based therapeutics market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the period 2021-2030. For this purpose, we have segmented the future opportunity across [A] target therapeutic area (hematological disorders, oncological disorders, ophthalmic diseases, infectious diseases and others) [B] approach of therapy (ex vivo and in vivo), [C] type of therapy (CAR-T cell therapy, HSC therapy, T cell therapy, and TIL), [D] key geographical regions (North America, Europe and Asia-Pacific). To account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industrys growth.

KEY QUESTIONS ANSWERED Who are the leading players engaged in the development of CRISPR based therapeutics? Which key clinical conditions can be treated by CRISPR based drugs? What are the investment trends in this industry? Which partnership models are commonly adopted by stakeholders engaged in this domain? How has the intellectual property landscape in this market evolved over the years? Which factors are likely to influence the evolution of this market? How is the current and future market opportunity likely to be distributed across key market segments?

RESEARCH METHODOLOGY The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This information is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include: Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views

While the focus has been on forecasting the market till 2030, the report also provides our independent views on various non-commercial trends emerging in this industry. This opinion is solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary and primary sources of information.

CHAPTER OUTLINES Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the CRISPR therapeutics market and its likely evolution in the short-mid to long term.

Chapter 3 provides a general introduction to CRISPR/Cas system. In addition, we have briefly described the components of CRISPR/Cas system, its mechanism of action and vehicles to deliver CRISPR/Cas components in to the target cells. The chapter lays emphasis on the applications of CRISPR technology. It also includes a discussion on the challenges associated with the use of CRISPR based therapeutics.

Chapter 4 presents a detailed assessment of the current market landscape of CRISPR based therapeutics, along with information on type of therapy (CAR-T therapy, HSC therapy, T cell therapy, Phage therapy and others), approach of therapy (in vivo and ex vivo), cell source (autologous and allogeneic), phase of development (discovery, preclinical and clinical), type of delivery vehicle used (viral vector, electroporation, LNPs, bacteriophage and others), target disease indication and therapeutic area (autoimmune disorders, cardiovascular diseases, dermatological disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, muscular diseases, neurological disorders, oncological disorders, ophthalmic diseases and others). In addition, it provides an overview of the CRISPR based therapeutics developer landscape, highlighting the players that are active in this domain. It includes information on their year of establishment, company size (in terms of number of employees) and location of headquarters of the drug developers. We have presented a logo landscape, highlighting the distribution of the drug developers based on company size and location of headquarters. Further, it presents an analysis on the initiatives of the big pharma companies in this domain.

Chapter 5 includes profiles of the key players engaged in the development of CRISPR based therapeutics (shortlisted based on strength of product portfolio). Each profile features a brief overview of the company, its financial information (if available), brief details of gene editing technology, therapeutic pipeline, recent developments and an informed future outlook.

Chapter 6 provides an in-depth analysis of the patents filed / granted for CRISPR technology since 2015. The analysis also highlights the key trends associated with these patents, including type of patent (granted patent, patent application and others), publication year, application year, geographical location / patent jurisdiction (North America, Europe, Asia-Pacific and Rest of the World), IPCR symbols, key inventors and leading industry / non-industry players. In addition, it includes a detailed patent benchmarking analysis of leading players and patent valuation analysis, which evaluates the qualitative and quantitative aspects of these patents.

Chapter 7 features a detailed analysis of the partnerships and collaborations that have been inked in this domain since 2014, covering research and licensing agreements, R&D agreements, licensing agreements, licensing and manufacturing agreement, product development and manufacturing agreements, joint ventures and other types of partnership deals. The chapter includes analysis based on year of partnership, type of partnership model, purpose of licensing deal, and most active player(s) (in terms of number of partnerships inked). In addition, the chapter features a discussion on the surrogate licensing practice in the CRISPR based therapeutics market.

Chapter 8 provides an analysis of the investments made since 2014 at various stages of development of companies engaged in this domain, based on the year of investment, number of funding instances, amount invested and type of funding, highlighting most active players (in terms of number of funding instances and amount raised) and most active investors (in terms of number of funding instances).

Chapter 9 presents an analysis of the start-ups (established after 2012 and having less than 200 employees) engaged in the development of CRISPR based therapeutics based on the parameters, such as number of candidates in discovery, preclinical and clinical phase of development, target therapeutic area, amount raised through funding, number of investors, type of funding, number of deals signed, and number of patents filed.

Chapter 10 features an elaborate discussion on the future market potential of various CRISPR based therapeutics. The chapter provides insights on the likely distribution of the current and forecasted opportunity across [A] target therapeutic area (hematological disorders, oncological disorders, ophthalmic diseases, infectious diseases and others) [B] approach of therapy (ex vivo and in vivo), [C] type of therapy (CAR-T cell therapy, HSC therapy, T cell therapy, and TIL) and [D] key geographical regions (North America, Europe and Asia-Pacific).

Chapter 11 is a summary of the overall report, highlighting the key facts and figures related to the research and analysis presented in the previous chapters.

Chapter 12 is a collection of interview transcripts of discussions held with representatives of renowned organizations engaged in the CRISPR technology domain. In this chapter, we have presented the insights on our conversation with Harrison Wong (Public Relations, Burns McClellan, for eGenesis).

Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which consists the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p06130494/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Read more:
CRISPR Based Therapeutics Market by Type of Therapy, Therapeutic Approach, Therapeutic Area, and Key Geographical Regions : Industry Trends and Global...

This article was originally published here

Life Sci. 2021 Aug 25:119908. doi: 10.1016/j.lfs.2021.119908. Online ahead of print.

ABSTRACT

Genetic disorders and congenital abnormalities are present in 2-5% of births all over the world and can cause up to 50% of all early childhood deaths. The establishment of sophisticated and controlled techniques for customizing DNA manipulation is significant for the therapeutic role in such disorders and further research on them. One such technique is CRISPR that is significant towards optimizing genome editing and therapies, metabolic fluxes as well as artificial genetic systems. CRISPR-Cas9 is a molecular appliance that is applied in the areas of genetic and protein engineering. The CRISPR-CAS system is an integral element of prokaryotic adaptive immunity that allows prokaryotic cells to identify and kill any foreign DNA. The Gene editing property of CRISPR finds various applications like diagnostics and therapeutics in cancer, neurodegenerative disorders, genetic diseases, blindness, etc. This review discusses applications of CRISPR as a therapeutic in various disorders including several genetic diseases (including sickle cell anemia, blindness, thalassemia, cystic fibrosis, hereditary tyrosinemia type I, duchenne muscular dystrophy, mitochondrial disorders), Cancer, Huntingtons disease and viral infections (like HIV, COVID, etc.) along with the prospects concerning them. CRISPR-based therapy is also being researched and defined for COVID-19. The related mechanism of CRISPR has been discussed alongside highlighting challenges involved in therapeutic applications of CRISPR.

PMID:34453943 | DOI:10.1016/j.lfs.2021.119908

View post:
Applications of CRISPR as a potential therapeutic - DocWire News

CRISPR Clinopathomics is an emerging science with applications in biotechnology and cellular biology. It is a genome-wide, single-gene-based technology to which various pharmacological agents can be added to promote disease resistance. It has great potential to address all life sciences challenges with an approach that allows for the production of multiple proteins that can attack many of lifes common challenges. This technology can potentially address most life-threatening diseases such as cancer, infections, inflammation, inherited disorders, diabetes, aging, neurological and other disorders, and chronic conditions, and possibly more.

FREE | Request Sample is Available @https://www.coherentmarketinsights.com/insight/request-sample/2598

*The Sample only consist ofTable of Content (ToC).Research Frameworkof the actual report.Research Methodologyadopted for it.

Major Company Profiles Covered in This Report:Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Technological advancements in the field of genome editing are expected to drive growth of the global CRISPR and CAS gene market during the forecast period. Key biopharmaceutical companies across the globe are focused on research and development activities, in order to innovate novel technologies in genome editing. For instance, in September 2020, Intellia Therapeutics Inc. presented new data demonstrating the efforts of In Vivo CRISPR/CAS9 edits to reduce a disease-causing protein or restore a functional protein.

Furthermore, in December 2020, Editas Medicine Inc., a genome editing company, submitted an investigational New Drug (IND) to the U.S. Food and Drug Administration (FDA), indicated for sickle cell disease. Such advancements and R&D activities have increased the demand for genome editing. Hence, these factors are expected to drive growth of the global CRISPR and CAS gene market during the forecast period. Moreover, increasing research in plant genome editing programs is expected to boost the global CRISPR and CAS gene market growth over the forecast period.

Request Free research report Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/2598

However, off-target effects associated with CRISPR technology such as deletions, unintended point mutations, and translocations are expected to hamper the global CRISPR and CAS gene market growth over the forecast period. Among regions, North America is expected to witness significant growth in the global CRISPR and CAS gene market during the forecast period. This is owing to various companies involved in gene editing and the development of novel therapeutics across the region. Moreover, Asia Pacific is expected to register a robust growth rate over the forecast period, owing to increasing popularity of CRISPR technology in the region.

Key companies involved in the global CRISPR and CAS gene market are CRISPR Therapeutics, Inscripta, Inc., AstraZeneca, Mammoth Biosciences, Addgene, Synthego, Caribou Biosciences, Inc., Takara Bio, Inc., Cellectis, New England BioLabs, Editas Medicine, Inc., Merck KGaA, F. Hoffmann-La Roche Ltd., Intellia Therapeutics, Inc., and Danaher Corporation.

For instance, in November 2019, Caribou Biosciences Inc., a CRISPR genome editing company, announced the results of a new study demonstrating human genome engineering with TYPE I CRISPR-CAS systems.

Inquire more about this report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2598

Some Notable Offerings by Coherent Market Insights Report on CRISPR and CAS Gene market:

We will provide you an analysis of the extent to which this CRISPR and CAS Gene market research report acquires commercial characteristics along with examples or instances of information that helps you to understand it better.

We will also help to identify customary/ standard terms and conditions, as offers, worthiness, warranty, and others.

Also, this report will help you to identify any trends to forecast growth rates.

The analyzed report will forecast the general tendency for supply and demand.

How Coherent Market Insights Assists in Making Strategic Moves For CRISPR and CAS Gene Market Manufacturer?

The data provided in the CRISPR and CAS Gene market report offers comprehensive analysis of important industry trends. Industry players can use this data to strategize their potential business moves and gain remarkable revenues in the upcoming period.

The report covers the price trend analysis and value chain analysis along with analysis of diverse offering by market players. The main motive of this report is to assist enterprises to make data-driven decisions and strategize their business moves.

Also, Research Report Examines:

Competitive companies and manufacturers in global market

By Product Type, Applications & Growth Factors

Industry Status and Outlook for Major Applications / End Users / Usage Area

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Originally posted here:
[PDF] CRISPR and CAS Gene Market Reflect Steady to Explore New Dimensions of Genome Engineering UNLV The Rebel Yell - UNLV The Rebel Yell

Its safe to say that before the development of the Pfizer-BioNTech and Moderna COVID-19 vaccines, most people hadnt thought about messenger RNA, or mRNA, since high school science classif ever. The molecule plays a pivotal role in the body, carrying the recipes for making various proteins to the parts of cells that produce them. But mRNA wasnt exactly a common phrase until Pfizer-BioNTech and Moderna harnessed the genetic materials power to teach the body to make a piece of a protein found on the COVID-19 virus surface, thus training it to fight the real thing, were it to attack.

The tremendous efficacy of mRNA-based COVID-19 vaccines has generated plenty of excitement about its potential use in vaccines for other diseases. And vaccines may be just the beginning. Last month, researchers used mRNA to deliver CRISPR gene-editing technology that could permanently treat a rare genetic disease in humansan advance that experts say has implications far beyond the treatment of a single condition.

Medical science research utilizing CRISPRa system that allows scientists to add, remove or change specific genetic information within the bodyhad already been advancing rapidly in recent years. Researchers have shown its potential for reversing blindness and sickle cell anemia, and to treat genetic diseases in animals. But new work described in the New England Journal of Medicine in June marks what researchers are calling the first time CRISPR has been shown to treat a genetic disorder when directly administered to human patients.

In this case, the technology was applied towards a therapy for transthyretin amyloidosis, a genetic disease that causes sufferers livers to produce a protein that eventually builds up to toxic levels. The diseases prevalence varies depending on patient demographicsit affects about one in 100,000 Americans of European descent, but as many as one in every 538 people in northern Portugal, for exampleand can be passed down to future generations. While there are drugs that can help patients manage the disease, the goal of the new research was to stop the problem at its source.

To imagine using [CRISPR] as a therapy for people, you need to figure out how to get these editing tools into the cells youre trying to fix. Thats where messenger RNA comes in, explains Daniel Anderson, a professor of chemical engineering at the Massachusetts Institute of Technology and a co-founder of CRISPR Therapeutics, which uses CRISPR technology to develop medications. Anderson was not involved in the research.

The research team, led by Dr. Julian Gillmore, an amyloidosis expert at the U.K.s Royal Free Hospital, programmed mRNA to deliver gene-editing instructions to the liver, shutting down the part responsible for producing the toxic protein. After a one-time injection of the drug, three of the six people in the trial saw an almost complete drop-off in protein production; the remaining three, who received a smaller dose, saw less dramatic results. It will take a few months to see if that accomplishment translates to symptom relief, but the early findings are promising. (The work was funded by pharmaceutical companies Intellia Therapeutics and Regeneron, which produce the injectable CRISPR drug.)

As Dr. John Leonard, Intellias president and CEO, puts it: mRNA is a way to make CRISPR gene editing come alive. CRISPR is the workhorse; mRNA encodes it.

In theory, the same general technology could be used to treat conditions beyond transthyretin amyloidosis. There are a host of diseases in the liver where this might work in an analogous manner, says Dr. Kenneth Chien, a senior professor of cardiology research at Swedens Karolinska Institutet and a co-founder of Moderna Therapeutics, who was not involved in the research. The most important aspect of this is the implications that the technology can be repurposed.

Chien has believed in mRNAs drug-development potential for more than a decade. When Moderna was founded in 2010, in fact, its chief goal was to develop mRNA-based drugs, not vaccines. (Chien no longer works at Moderna and is now an advisor to the pharmaceutical giant AstraZeneca.) He continues to work on an mRNA-based drug he hopes could eventually treat heart conditions.

The tricky part, Leonard says, is figuring out how to get a drug into different tissues, since the strategy for delivering CRISPR-based therapeutics varies depending on its target. The new research offers a blueprint for liver-based conditions, and Leonard believes similar approaches could be used in the near-term for bone-marrow, nervous-system and muscle diseases. The list theoretically grows from there, so long as researchers can fine-tune delivery.

COVID [vaccines are] a big success for mRNA, and if it does nothing else, its been great, Chien says. However, I think youre going to see the next chapter of mRNA is going to be as exciting, if not more so, than the story of mRNA vaccines.

For your security, we've sent a confirmation email to the address you entered. Click the link to confirm your subscription and begin receiving our newsletters. If you don't get the confirmation within 10 minutes, please check your spam folder.

Write to Jamie Ducharme at jamie.ducharme@time.com.

More:
MRNA's Next Chapter Has Nothing to Do With COVID-19 Vaccines - TIME

- More than 45 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021-

-Received Orphan Drug Designation (ODD) for Phase 1 clinical trial of CTX130 for the treatment of T-cell lymphoma-

-Enrollment ongoing in CTX110, CTX120 and CTX130 clinical trials-

ZUG, Switzerland and CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the second quarter ended June 30, 2021.

We concluded an important quarter in which we reported notable data from our hemoglobinopathies program while rapidly advancing our entire clinical and pre-clinical portfolio and our capabilities, said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. Updated clinical data on CTX001 presented at EHA demonstrate consistency and durability, further validating the promise of a functional cure for sickle cell disease and beta thalassemia. We expect to report clinical data from our immuno-oncology programs later this year, and to file multiple INDs for our regenerative medicine and in vivo programs in the next 18 to 24 months.In addition, we continue to expand our portfolio and access best-in-class capabilities through collaborations, such as those recently announced with Capsida Biotherapeutics and Nkarta Therapeutics.

Recent Highlights and Outlook

Second Quarter 2021 Financial Results

About CTX001CTX001 is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for patients suffering from TDT or severe SCD, in which a patients hematopoietic stem cells are edited to produce high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is a form of the oxygen-carrying hemoglobin that is naturally present at birth, which then switches to the adult form of hemoglobin. The elevation of HbF by CTX001 has the potential to alleviate or eliminate transfusion requirements for patients with TDT and reduce or eliminate painful and debilitating sickle crises for patients with SCD. Earlier results from these ongoing trials were published as a Brief Report in The New England Journal of Medicine in January of 2021.

Based on progress in this program to date, CTX001 has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for both TDT and SCD. CTX001 has also been granted Orphan Drug Designation from the European Commission, as well as Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), for both TDT and SCD.

Among gene-editing approaches being investigated/evaluated for TDT and SCD, CTX001 is the furthest advanced in clinical development.

About the CRISPR-Vertex CollaborationVertex and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. CTX001 represents the first potential treatment to emerge from the joint research program. Under a recently amended collaboration agreement, Vertex will lead global development, manufacturing and commercialization of CTX001 and split program costs and profits worldwide 60/40 with CRISPR Therapeutics.

About CLIMB-111The ongoing Phase 1/2 open-label trial, CLIMB-Thal-111, is designed to assess the safety and efficacy of a single dose of CTX001 in patients ages 12 to 35 with TDT. The trial will enroll up to 45 patients and follow patients for approximately two years after infusion. Each patient will be asked to participate in a long-term follow-up trial.

About CLIMB-121The ongoing Phase 1/2 open-label trial, CLIMB-SCD-121, is designed to assess the safety and efficacy of a single dose of CTX001 in patients ages 12 to 35 with severe SCD. The trial will enroll up to 45 patients and follow patients for approximately two years after infusion. Each patient will be asked to participate in a long-term follow-up trial.

About CLIMB-131This is a long-term, open-label trial to evaluate the safety and efficacy of CTX001 in patients who received CTX001 in CLIMB-111 or CLIMB-121. The trial is designed to follow participants for up to 15 years after CTX001 infusion.

About CTX110CTX110, a wholly owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19, or CD19. CTX110 is being investigated in the ongoing CARBON trial.

About CARBONThe ongoing Phase 1 single-arm, multi-center, open label clinical trial, CARBON, is designed to assess the safety and efficacy of several dose levels of CTX110 for the treatment of relapsed or refractory B-cell malignancies.

About CTX120CTX120, a wholly-owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen, or BCMA. CTX120 is being investigated in an ongoing Phase 1 single-arm, multi-center, open-label clinical trial designed to assess the safety and efficacy of several dose levels of CTX120 for the treatment of relapsed or refractory multiple myeloma. CTX120 has been granted Orphan Drug designation from the FDA.

About CTX130CTX130, a wholly-owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 70, or CD70, an antigen expressed on various solid tumors and hematologic malignancies. CTX130 is being developed for the treatment of both solid tumors, such as renal cell carcinoma, and T-cell and B-cell hematologic malignancies. CTX130 is being investigated in two ongoing independent Phase 1, single-arm, multi-center, open-label clinical trials that are designed to assess the safety and efficacy of several dose levels of CTX130 for the treatment of relapsed or refractory renal cell carcinoma and various subtypes of lymphoma, respectively.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR THERAPEUTICS word mark and design logo, CTX001, CTX110, CTX120, and CTX130 are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

CRISPR Therapeutics Forward-Looking StatementThis press release may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Kulkarni in this press release, as well as statements regarding CRISPR Therapeutics expectations about any or all of the following: (i) the safety, efficacy and clinical progress of CRISPR Therapeutics various clinical programs, including CTX001, CTX110, CTX120 and CTX130; (ii) the status of clinical trials and preclinical studies (including, without limitation, the expected timing of data releases and development, as well as initiation and completion of clinical trials) and development timelines for CRISPR Therapeutics product candidates; (iii) the data that will be generated by ongoing and planned clinical trials, and the ability to use that data for the design and initiation of further clinical trials or to support regulatory filings, including expectations regarding the CTX001 data; (iv) the actual or potential benefits of regulatory designations; (v) the potential benefits of CRISPR Therapeutics collaborations and strategic partnerships; (vi) the intellectual property coverage and positions of CRISPR Therapeutics, its licensors and third parties as well as the status and potential outcome of proceedings involving any such intellectual property; (vii) the sufficiency of CRISPR Therapeutics cash resources; and (viii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the potential for initial and preliminary data from any clinical trial and initial data from a limited number of patients not to be indicative of final trial results; the potential that clinical trial results may not be favorable; that one or more of CRISPR Therapeutics internal or external product candidate programs will not proceed as planned for technical, scientific or commercial reasons; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics product candidates; uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics product candidates (including, without limitation, availability and timing of results and whether such results will be predictive of future results of the future trials); uncertainties about regulatory approvals to conduct trials or to market products; the potential impacts due to the coronavirus pandemic such as (x) delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; (y) the timing and progress of clinical trials, preclinical studies and other research and development activities; and (z) the overall impact of the coronavirus pandemic on its business, financial condition and results of operations; uncertainties regarding the intellectual property protection for CRISPR Therapeutics technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics most recent annual report on Form 10-K, quarterly report on Form 10-Q, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel Eides+1-617-315-4493rachel.eides@crisprtx.com

CRISPR Therapeutics AGCondensed Consolidated Statements of Operations(Unaudited, In thousands except share data and per share data)

CRISPR Therapeutics AGCondensed Consolidated Balance Sheets Data(Unaudited, in thousands)

View original post here:
CRISPR Therapeutics Provides Business Update and Reports - GlobeNewswire

CRISPR Therapeutics AG (CRSP) came out with quarterly earnings of $9.44 per share, beating the Zacks Consensus Estimate of $4.19 per share. This compares to loss of $1.30 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 125.30%. A quarter ago, it was expected that this company would post a loss of $1.45 per share when it actually produced a loss of $1.51, delivering a surprise of -4.14%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

CRISPR Therapeutics AG, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $900.7 million for the quarter ended June 2021, surpassing the Zacks Consensus Estimate by 32.84%. This compares to year-ago revenues of $0.04 million. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

CRISPR Therapeutics AG shares have lost about 21.8% since the beginning of the year versus the S&P 500's gain of 17.2%.

What's Next for CRISPR Therapeutics AG?

While CRISPR Therapeutics AG has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Story continues

Ahead of this earnings release, the estimate revisions trend for CRISPR Therapeutics AG was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.38 on $4.29 million in revenues for the coming quarter and $0.66 on $457.55 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 21% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCRISPR Therapeutics AG (CRSP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

See the original post:
CRISPR Therapeutics AG (CRSP) Tops Q2 Earnings and Revenue Estimates - Yahoo Finance

COLLEGE PARK, Md. -- With two new funding sources, Yiping Qi, associate professor in the Department of Plant Science & Landscape Architecture (PSLA) at the University of Maryland (UMD), continues his work to expand the reach and utility of CRISPR gene editing technologies. Funded by the United States Department of Agricultures National Institute of Food and Agriculture (USDA-NIFA), Qi and his team will be testing new delivery technologies for CRISPR-Cas12a to develop a pipeline for genome editing in carrots. This could lead to the production of more nutritious and hypoallergenic carrot varieties that can be quickly introduced into the marketplace. Additionally, Qi will continue his search for novel CRISPR-Cas12a variants with funding from the Maryland Innovation Initiative (MII), with the ultimate goal of finding more CRISPR tools that are optimized for crop production.

With this new USDA funding, we are excited to showcase CRISPR-Cas12a gene editing technologies that my lab has been working on in carrots as an important vegetable, says Qi. The major innovations in this work are really in the delivery mechanisms that can make targeted and precise edits without the production of a highly regulated GMO [genetically modified organism]. But we also want to explore more CRISPR-Cas12a variants that can be useful for crop production, so the MII grant provides that support.

As Qi explains, most current methods for targeted mutations or precise genome edits rely on the use of transgenes (transferring a gene from one organism to another) that would then be regulated as GMOs. This is typically done by delivering genetic material with agrobacteria used to infect the plants and transfer the desired trait. However, for carrots, Qi is testing different delivery methods that use readily available proteins and guiding molecules to deliver the same material without using agrobacteria and transgenes. This method is new to carrots, and would allow new varieties to make it to market much faster without the need for GMO regulations.

Hopefully, we can take advantage of these technologies to develop some interesting and useful plants that have consumer benefits, says Qi. For example, we are targeting a gene to help the carrot accumulate more beta carotene, which can boost nutritional value. We are also targeting two genes that can potentially be knocked out to create a hypoallergenic carrot that could be eaten by those with certain allergies.

These varieties could not only be useful in and of themselves, but the work will establish a process for genome editing in carrots that hasnt been previously developed. This will save substantial time over traditional breeding, and Qi hopes will inspire many researchers and breeders to consider the possibilities of this technology in crops like carrots.

The whole project is to develop new technology for genome editing in more niche or minor crops that can have major impacts, stresses Qi. Not much work has been previously done in carrots, and I hope this will open up a lot of doors for gene editing in other root vegetables and more.

In addition to this work with the known variants of CRISPR-Cas12a, Qi is continuing his search for novel variants that are optimal for crop genome editing. Qis recent work contributing six novel variants of CRISPR-Cas12a (never before proven in plants) was named UMD Life Sciences Innovation of the Year. These patent-pending tools widen the scope of what CRISPR-Cas12a can do in plants, which can help to produce food more effectively to fight hunger.

With new funding from MII, Qi will continue to explore new patentable CRISPR variants, hoping to find more tools that work efficiently at lower temperatures. For work in human cells, gene editing is happening at the temperature of the human body, which is almost 100 degrees Fahrenheit, says Qi. This is the optimal temperature for most CRISPR systems, but this isnt the best temperature for doing work in plants. All that work needs to be done around room temperature where plants can comfortably grow. So finding tools that are optimized for this lower temperature application is important for advancing genome editing in crops.

Qis team has established a proprietary pipeline for identifying new candidate CRISPR variants, and he will first test these candidates in rice and tomatoes to expand the scope of gene editing in crops.

This work is funded by the United States Department of Agricultures National Institute of Food and Agriculture (USDA-NIFA), Award #2021-67013-34554, and the Maryland Innovation Initiative (MII).

Read more:
UMD Research Aims To Develop A Genome Editing Pipeline In Carrots, Optimize Crop Production - Bay Net

COLLEGE PARK, Md. (WJZ) A professor at the University of Maryland in College Park has received new funding from two sources to continue research into CRISPRgenomeeditingtechnologies, withthegoal of enhancing crop productionand feeding a growing global population, according to a university statement.

Yiping Qi, associate professor in the Department of Plant Science & Landscape Architecture, received the funds from the U.S. Department of Agricultures National Institute of Food and Agriculture to develop a pipelineforgenomeediting in carrots that could lead to more nutritious and hypoallergenic carrot varieties in stores. He also received funding from theMaryland Innovation Initiative to continue his search for novel CRISPR-Cas12 variants. That goal is to find more CRISPR tools that are optimized for crop production.

Qi is testing delivery methods that use readily available proteins and guiding molecules to deliver the same material most current methods for targeted mutations use, transferring a gene from organisms to another that would then be regulated as genetically modified organisms.

This method is new to carrots and would allow new varieties to make it to market more quickly without the need for GMO regulations, according to the statement.

With the MII funding, he will continue exploring new patentable CRISPR variants, hoping to find more tools that work efficiently at lower temperatures.

Qis team has established a proprietary pipeline for identifying new candidate CRISPR variants, and he will first test these candidates in rice and tomatoes to expand the scope of gene editing in crops.

Read this article:
University Of Maryland Professor Gets New Funds To Continue Research To Enhance Crop Production - CBS Baltimore

Its hard to put just one label on Aaron Ciechanover. He was awarded the Nobel Prize in Chemistry for characterizing the method that cells use to degrade and recycle proteins usingubiquitin, but his background stems from biology, and he was also trained as a medical doctor and a surgeon. When it comes to understanding the intricacies around human health, few people on Earth can claim the broad view that Ciechanover has.

Which is why, when he says hes excited about whats to come in medicine, its hard not to share his excitement.

The future of medicine is going to be revolutionary, Ciechanover said at the 2021 Lindau Nobel meeting, which took place online this year due to the pandemic. The meetings bring together Nobel laureates and young scientists to foster scientific exchange.

Back in the days when Ciechanover was studying medicine, he recalls, things were very different.

Lets say, if a patient had a tumor, we were not interested in the molecular mechanism that underlies the tumor development, because we did not have the tools to study it, he says.

The procedure was simplistic and straightforward. Doctors would look at the imaging facilities they had access to at the time (either X-ray, CT Scan, or MRI) and decide whether the tumor could be operated on. Surgery was generally the preferred procedure because the tumor mass could be extracted. If the tumor was too big or was touching essential organs, then doctors would try to decrease its size using chemotherapy or radiation, and then try surgery.

But these were (and still are) very harsh measures, with harsh side effects.

They are like shooting a fly with a cannon. They are not discriminating between the healthy tissue and the sick tissue, they are very difficult to direct, Ciechanover explains.

Then, at the turn of the century, a revolution started unfolding. In 2000, a landmark paper published in the journal Nature opened the floodgates of genetic discovery.

I remember it very well, this exciting day when Nature magazine came out with the first human genome. The first human genome gave us the information, the library of what we are made of. This was really the very beginning, but the last 20 years have seen enormous progress. We are now able to diagnose the disease much better [..] and we are able to analyze tumors or any other disease at the molecular level.

Heres a sense of how much things have progressed. The price of whole human genome sequencing was around $2.7 billion in 2003. Today, its under $100. Advancements in technology and decrease in price has made genetic and molecular analyses more widely available, and its not about to stop.

We are developing dedicated tools to stop the tumor or the disease at large, with a very gentle tool directing a bullet direction at the underlying mechanism, Ciechanover adds.

Even with conventional medicine, healthcare has benefited tremendously. Things like imaging, antibiotics, vaccines, operating procedures, and so on, have made a tremendous difference in how we treat patients. But now we are into a much bigger revolution, Ciechanover believes. He foresees a future where the very definition of medicine will change. Finally, we will start treating patients, not diseases, and patients will receive individualized treatments.

Tasuku Honjo is also optimistic. He believes that while cancer wont be eradicated anytime soon, theres a good chance well be able to keep most cancers in check.

Honjo should know. He and his colleagues discovered a molecule called programmed cell death protein 1 (PD-1). They also showed that this molecule functions as a sort of braking system for acquired immunity making sure that your immune system doesnt go into overdrive and cause autoimmune disease. But too much PD-1, and the immune system would not do its job properly.

For instance, several tumors produce something similar to PD-1, which helps the tumors escape the immune system. But if PD-1 could be suppressed in cancer patients, then we could use peoples own immune systems to fight cancer. This is exactly what Honjo says can help keep cancers in check.

Honjo and colleagues found that blocking PD-1 in mice can cure tumors by reactivating acquired immunity in 2002. Then, in a landmark moment in 2014, the treatment of cancer in humans by PD-1 blockade was approved by regulatory bodies in Japan and the USA. Now, there are over 1,000 clinical trials happening in the world, and PD-1 treatments seem to be effective against a wide variety of cancers, with long-lasting positive effects.

Another Nobel-winning discovery that could help our fight against cancer is CRISPR/Cas9.

CRISPR is becoming a mainstream methodology used in many cancer biology studies because of the convenience of the technique, says Jerry Li of NCIsDivision of Cancer Biology.

CRISPR is a relatively simple but very powerful and accurate way to edit genes. It was inspired by nature, from a defense mechanism some bacteria use to protect themselves against viral invasions. The bacterium captures snippets of any virus intruders DNA and stores it as segments called CRISPRs. If the same virus returns and tries to attack again, the bacterium searches its DNA library and releases an enzyme called Cas to slice up the invaders DNA.

Gene editing is not new, ProfessorEmmanuelle Charpentier, one of the pioneers behind CRISPR explained at the Lindau Nobel meeting. But thanks to the work of Charpentier and Jennifer Doudna, who were awarded the 2020 Nobel Prize, we have access to unprecedented tools.

The first CRISPR cancer therapy was launched in 2019. The goal of the study is to edit patients own immune cells to better detect and kill cancer. The treatment is safe, and early results are encouraging but CRISPR is still just getting warmed up.

This [trial] was really a proof-of-principle, feasibility, and safety thing that now opens up the whole world of CRISPR editing and other techniques of [gene] editing to hopefully make the next generation of therapies, said Edward Stadtmauer, M.D., of the University of Pennsylvania, who is involved with the research.

Weve come a long way in our fight against cancer in the past half-century, but despite improving diagnosis and treatments, theres still more work to be done if we want to keep cancer in check. But the tools we need to do so are now coming in.

With approaches like CRISPR or PD-1, researchers can develop customized, efficient treatments with few side effects. Thanks to the likes of Honjo, Charpentier, and Ciechanover, we are witnessing a new revolution of medicine, and its hard not to share their enthusiasm for whats to come.

Its still early days and there are plenty of hurdles to be overcome, but the science is progressing in leaps and bounds. It may not be today or tomorrow, but were gathering the weapons to fight cancer and its shaping up to be a big arsenal.

Read the original:
A revolution against cancer is unfolding and were just getting started - ZME Science

CRISPR Therapeutics (CRSP) is one of my favorite biotech companies as the big leader among gene-editing pioneers.

But I had to let the stock go -- right before shares launched into the December ASH meeting (American Society of Hematology) -- because analysts were so bearish on the outlook for when the R&D pipeline would produce any revenues, much less profits.

Of course, talking about revenues and profits for world-changing, early-stage medical science is almost always a non sequitur.

Still in late summer, I let go of my CRSP shares for a 71% gain. But as I describe in this September video and article, it was not the first, nor the last, of great trading gains in the greatest of CRISPR companies...

CRISPR Stocks: Buy or Trade?

In fact, here's the actual trading record from my Healthcare Innovators portfolio of my previous 3 CRSP trades...

So why did CRSP launch from $110 to $210 in December and January?

It was mostly about investors recognizing that the company's early data in treating debilitating illnesses like Sickle Cell Disease (SCD) could indeed become world-changing for millions afflicted with the genetic impairment to their red blood cells.

SCD comprises a group of disorders that cause red blood cells to become misshapen and break down. Red blood cells contort into a sickle shape, and die early, leaving a shortage of healthy red blood cells (sickle cell anemia), and can block blood flow causing pain (sickle cell crisis). Infections, pain, and fatigue are symptoms of sickle cell disease. Current treatments include frequent medications, blood transfusions and, in extreme cases, a bone-marrow transplant -- but no cures.

As Antonio Regalado wrote in the MIT Technology Review wrote last week, "The burden of sickle-cell, an inherited disease that shortens lives by decades (or, in poor regions, kills during childhood), falls most heavily on Black people in equatorial Africa, Brazil, and the US. HIV has also become a lingering scourge: about two-thirds of people living with the virus, or dying from it, are in Africa."

I explained some of this potential in this vlog on December 10...

CRISPR Gene Editing: Owning the Future of Medicine

A secondary "igniter" of all CRISPR stocks launching higher in Dec-Jan (besides my video commentaries linked above) was the investment activity of Cathie Wood and her revolutionary ETF firm ARK Invest.

I produced a video and article about her one-woman investor revolution in early January with her monster ETFs ARK Innovation (ARKK) and ARK Genomics (ARKG)...

How Cathie Put the Wood to Wall Street: TSLA, SQ, ROKU, CRSP, BIDU

There will be a time to buy CRSP again. But as with all emerging Biotechs, you sometimes have to wait for the next clinical data catalyst -- or an M&A one.

I'm betting the latter is the sooner driver of the next move from a $10 billion market cap to a $20 billion one.

Meanwhile, I own the smaller pair of Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) near $5 billion.

Stay CRSPy!

Cooker

Kevin Cook is a Senior Stock Strategist for Zacks Investment Research where he runs the Healthcare Innovators portfolio.

Just Released: Zacks 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.9% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intellia Therapeutics, Inc. (NTLA) : Free Stock Analysis Report

CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The rest is here:
Bear of the Day: CRISPR Therapeutics (CRSP) - Yahoo Finance

For Immediate Release

Chicago, IL February 11, 2021 Zacks Equity Research Shares of Meridian Bioscience, Inc. VIVO as the Bull of the Day, CRISPR Therapeutics AG CRSP as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Tilray, Inc. TLRY and Uber Technologies, Inc. UBER.

Here is a synopsis of all four stocks:

Meridian Bioscienceis a $1 billion provider of diagnostic test kits for gastrointestinal and respiratory infectious diseases. The company is expected to grow sales 32% this year to $335 million.

And after reporting a strong beat-and-raise quarter last week, analysts had to boost their EPS estimates over 30% from $1.24 to $1.63. So VIVO is back to a Zacks #1 Rank, sporting a projected 52% rise in profits.

I wrote about VIVO in early January and said it wasn't too late for investors to grab hold of this profit rocket near $20 per share...

"Bottom line on VIVO: I always pay attention to small companies growing their sales rapidly as they could become acquisition targets by larger biopharma or MedTech players. Buying VIVO near $20 offers excellent risk/reward, with or without an M&A suitor."

And then last week, right before the company report, I produced a video and article where I talked about why the COVID-19 testing stocks were under-appreciated given their fantastic growth...

Biotech Bonanza: COVID Launches Science at Warp Speed

Well here we are as VIVO pushed to 13-year highs above $30 with the earnings surprise and strong upside guidance.

Following the quarterly report, Piper Sandler analyst Steven Mah, a consistently bullish VIVO fan, raised his price target on Meridian Bioscience to $34 from $26 and reiterated an Overweight rating. Mah believes the company guidance was once again "very conservative" citing management's "pragmatic approach given the limited visibility on the durability of COVID-19 tailwinds."

Mah explained his increased confidence in Meridian's longer-term COVID-19 tailwinds given the Biden Administration's testing stance, slower than expected vaccine rollout, and new strain emergence.

Story continues

Meridian Bioscience develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. They describe their mission as helping providers make better diagnostic decisions with a focus on gastrointestinal, neonatal, pediatrics, and respiratory conditions.

The Diagnostics segment offers testing platforms, including real-time PCR (polymerase chain reaction) amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand.

I have written often in the past few months of specialized diagnostic companies likeQuidelandHologicas they build new revenue streams from SARS-CoV-2 testing. These revenue streams are likely sustainable as the virus mutates and requires modified tests.

And I recently bought shares of VIVO for the Zacks Healthcare Innovators portfolio because I liked the growth outlook for this small player in a rapidly expanding market for rapid diagnostics -- including coronavirus testing which will continue to be part of our lives for years to come, even with vaccines.

While Meridian Bioscience is a David among diagnostic Goliaths, its long and fascinating history surprised me. From the company website...

In 1977, Bill Motto founded Meridian Bioscience on a $500 investment in his Cincinnati homes basement. Meridians first product was distributing a rapid fungal test developed by the University of Kentucky. While calling on his hospital and research customers, Bill noticed there was no easy, clean way to transport patient samples. He developed the innovative Para-Pak stool transport system to meet this need.

As the product line grew, so did Meridians research and development, leading to a breakthrough in 1982 with a 10-minute rapid test for strep throat. Before the Meridian test, doctors would have to wait for two to three days for a culture result. Innovation continued as the company brought several cutting edge diagnostic technologies to market, including a DNA testing platform and first-of-their-kind tests for C. difficile, E. coli, H. pylori amongst others.

The new bottom line on VIVO:I continue to hold the shares and would recommend new positions between $25 and $27 looking for new bull market highs above $30 by June.

Disclosure: I own shares of QDEL, HOLX, and VIVO for the Zacks Healthcare Innovators portfolio.

CRISPR Therapeuticsis one of my favorite biotech companies as the big leader among gene-editing pioneers.

But I had to let the stock go -- right before shares launched into the December ASH meeting (American Society of Hematology) -- because analysts were so bearish on the outlook for when the R&D pipeline would produce any revenues, much less profits.

Of course, talking about revenues and profits for world-changing, early-stage medical science is almost always a non sequitur.

Still in late summer, I let go of my CRSP shares for a 71% gain. But as I describe in this September video and article, it was not the first, nor the last, of great trading gains in the greatest of CRISPR companies...

CRISPR Stocks: Buy or Trade?

So why did CRSP launch from $110 to $210 in December and January?

It was mostly about investors recognizing that the company's early data in treating debilitating illnesses like Sickle Cell Disease (SCD) could indeed become world-changing for millions afflicted with the genetic impairment to their red blood cells.

SCD comprises a group of disorders that cause red blood cells to become misshapen and break down. Red blood cells contort into a sickle shape, and die early, leaving a shortage of healthy red blood cells (sickle cell anemia), and can block blood flow causing pain (sickle cell crisis). Infections, pain, and fatigue are symptoms of sickle cell disease. Current treatments include frequent medications, blood transfusions and, in extreme cases, a bone-marrow transplant -- but no cures.

As Antonio Regalado wrote in the MIT Technology Review wrote last week, "The burden of sickle-cell, an inherited disease that shortens lives by decades (or, in poor regions, kills during childhood), falls most heavily on Black people in equatorial Africa, Brazil, and the US. HIV has also become a lingering scourge: about two-thirds of people living with the virus, or dying from it, are in Africa."

I explained some of this potential in this vlog on December 10...

CRISPR Gene Editing: Owning the Future of Medicine

A secondary "igniter" of all CRISPR stocks launching higher in Dec-Jan (besides my video commentaries linked above) was the investment activity of Cathie Wood and her revolutionary ETF firm ARK Invest.

I produced a video and article about her one-woman investor revolution in early January with her monster ETFsARK Innovation:

How Cathie Put the Wood to Wall Street: TSLA, SQ, ROKU, CRSP, BIDU

There will be a time to buy CRSP again. But as with all emerging Biotechs, you sometimes have to wait for the next clinical data catalyst -- or an M&A one.

I'm betting the latter is the sooner driver of the next move from a $10 billion market cap to a $20 billion one.

Stay CRSPy!

Cooker

Kevin Cook is a Senior Stock Strategist for Zacks Investment Research where he runs the Healthcare Innovators portfolio.

Markets continued to hover close to the zero-line as of Wednesdays close, with just the Dow finishing in the green among major indexes. The blue-chips rose 0.20% for a new all-time high, while the Nasdaq, S&P 500 and Russell 2000 all took a breather: -0.25%, -0.03% and -0.72% on the day.

One of the major pot stocks we discussed yesterday in this space,Tilray, continues its big run in what looks more like the latest short-squeeze stock, with Reddit groups now piling into the marijuana-based pharmaceutical company of late. Shares shot up another 51% Wednesday, following a +44% performance yesterday; Tilray is now up 400% in just the last month alone.

For sure, increased acceptance in U.S. states and countries around the world are a reason for the stock to do well. However, its market cap has more than doubled and the company has no P/E because it is forecast for negative earnings both in the upcoming quarterly report and full fiscal year. Tilray is up another 10% in late trading, up near $71 per share. This stock was trading at $19 per share on February 1st.

Uber followed a nice 6% bump in regular-day Wednesday trading with a worse-than-expected fiscal Q3 report, missing on the bottom line by a penny to -54 cents per share (though still better than the -64 cents the company reported in the year-ago quarter). Revenues grew $3.17 billion in the quarter, well off the expected pace of $3.55 billion in the Zacks consensus. Yet shares are only selling off minimally in the after-market; the company still says its on track to its profitability goal in 2021.

Though Uber posted a net loss per year of $6.8 billion on ride-sharing revenues down 52% year over year, its Uber Eats delivery service grew 224% in its fiscal Q3. Monthly active platform consumers gained a million more than predicted in the quarter, +93 million. And when one figures in the ride-sharing comeback seemingly inevitable as the Covid-19 pandemic is finally beaten back with vaccinations, we see that Uber looks to have weathered its worst-possible storm and survived.For more on UBER's earnings, click here.

Speaking of the coronavirus, nearly 45 million vaccination doses have now been administered, and the post-holiday season peak now looks to have been successfully scaled. We are now back to 7-day case rates back where they were in October and, importantly, pointed in the right direction. More than 27 million Americans have reportedly contracted Covid-19, leading to more than 466K fatalities. More good news: the death rate is now flat for those whove gotten the worst of the disease.

Questions or comments about this article and/or its author? Click here>>

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that have beaten the market more than 2X over with a stunning average gain of +24.9% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. http://www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumedthat any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein andis subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportMeridian Bioscience Inc. (VIVO) : Free Stock Analysis ReportCRISPR Therapeutics AG (CRSP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.

Read more:
Meridian Bioscience, CRISPR Therapeutics, Tilray and Uber highlighted as Zacks Bull and Bear of the Day - Yahoo Finance

The Global CRISPR Technology Market was valued at USD 696.7 Million in 2020 and is forecasted to reach USD 3.94 Bn at a CAGR of +24% by 2028.

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: its a way of finding a specific bit of DNA inside a cell. After that, the next step in CRISPR gene editing is usually to alter that piece of DNA.

CRISPR-Cas9 was adapted from a naturally occurring genome editing system in bacteria. The bacteria capture snippets of DNA from invading viruses and use them to create DNA segments known as CRISPR arrays. The CRISPR arrays allow the bacteria to remember the viruses (or closely related ones).

With CRISPR, scientists can create a short RNA template in just a few days using free software and a DNA starter kit that costs $65 plus shipping. Unlike protein-based technologies, the RNA in CRISPR can be reprogrammed to target multiple genes.

The company has a healthy balance sheet with $1.4 billion in cash and very little debt. CRISPR has the financial flexibility to fund its research programs for many more years to come. So it can prove to be an attractive investment for healthcare investors in the next five years.

Request for a sample report here @ https://www.reportconsultant.com/request_sample.php?id=43967

Major Players Covered in this Report:

CRISPR Technology Market Study assures you to advise higher than your competition. With Structured tables and figures examining the CRISPR Technology, the research document provides you a leading product, submarkets, revenue size and forecast to 2028.

The study report offers a comprehensive analysis of CRISPR Technology market size across the globe as regional and country level market size analysis, CAGR estimation of market growth during the forecast period, revenue, key drivers, competitive background and sales analysis of the payers. Along with that, the report explains the major challenges and risks to face in the forecast period.

The research report of the CRISPR Technology market offers broad analysis about the industry on the basis of different key segments. Moreover, the research report presents a comprehensive analysis about the opportunities, new products, and technological innovations in the market for the players.

Additionally, the research report on CRISPR Technology market provides an in depth analysis about market status, market size, revenue share, industry development trends, products advantages and disadvantages of the enterprise, enterprise competition pattern, industrial policy and regional industrial layout characteristics. Thus the study report offers a comprehensive analysis of market size across the globe as regional and country level market size analysis, estimation of market growth during the forecast period.

Get reports for upto 40% discount @ https://www.reportconsultant.com/ask_for_discount.php?id=43967

Market segmentation by Product Type:

Market segmentation by Applications:

Market segmentation by regions:

This study also covers company profiling, specifications and product picture, sales, market share and contact information of various regional, international and local vendors of Global CRISPR Technology Market. The market opposition is frequently developing greater with the rise in scientific innovation and M&A activities in the industry. Additionally, many local and regional vendors are offering specific application products for varied end-users. The new merchant applicants in the market are finding it hard to compete with the international vendors based on reliability, quality and modernism in technology.

Detailed TOC of CRISPR Technology Market Research Report-

CRISPR Technology Introduction and Market Overview

CRISPR Technology Market, by Application

CRISPR Technology Industry Chain Analysis

CRISPR Technology Market, by Type

Industry Manufacture, Consumption, Export, Import by Regions

Industry Value ($) by Region

CRISPR Technology Market Status and SWOT Analysis by Regions

Major Region of CRISPR Technology Market

Major Companies List

Conclusion

About Us:

Report Consultant A worldwide pacesetter in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly by taking calculative risks leading to lucrative business in the ever-changing market. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies.

Our research reports will give you the most realistic and incomparable experience of revolutionary market solutions. We have effectively steered business all over the world through our market research reports with our predictive nature and are exceptionally positioned to lead digital transformations. Thus, we craft greater value for clients by presenting progressive opportunities in the global futuristic market.

Contact us:

Rebecca Parker

(Report Consultant)

sales@reportconsultant.com

http://www.reportconsultant.com

Continue reading here:
CRISPR Technology Market hits at $3.94 Bn by 2028 with Thermo Fisher Scientific, Merck KGaA, GenScript, Integrated DNA Technologies (IDT) - The...

California headquartered, Caribou, isa clinical-stage CRISPR genome editing biotechnology company.

The collaboration leverages Caribous next-generation CRISPR genome editing technology platform and AbbVies antigen-specific binders. AbbVie will utilize Caribous next-generation Cas12a CRISPR hybrid RNA-DNA (chRDNA) genome editing and cell therapy technologies to research and develop two new CAR-T cell therapies.

Under the terms of deal, Caribou will receive US$40m in an upfront cash payment and equity investment and up to US$300m in future development, regulatory, and launch milestones.

Although allogeneic CAR-T cell therapies have shown early promise in some cancer patients, the need for overcoming the rejection of allogeneic CAR-T cells by the host immune system remains a key challenge to their broader development, said the companies.

Employing Caribous CRISPR genome editing platform to engineer CAR-T cells to withstand host immune attack would enable the development of the next-generation cellular therapies to benefit a broader patient population, claim the partners.

Caribou will conduct certain pre-clinical research, development, and manufacturing activities for the collaboration programs, and AbbVie will reimburse Caribou for all such activities pursuant to the collaboration, while AbbVie will be responsible for all clinical development, commercialization, and manufacturing efforts.

AbbVie also has the option to pay a fee to expand the collaboration to include up to an additional two CAR-T cell therapies.

We are excited to partner with AbbVie on the development of new CAR-T cell therapies. This collaboration validates Caribous differentiated next-generation CRISPR genome editing technologies that provide best-in-class efficiency and specificity, said Rachel Haurwitz, CEO of Caribou.

CAR-T therapies have shown to be a promising breakthrough in cancer treatment, Collaborating with Caribou and their cutting-edge CRISPR platform will help AbbVie advance our efforts to deliver new hope for patients, said Steve Davidsen, VP, oncology discovery, AbbVie.

Outside of this collaboration, Caribou is advancing an internal pipeline of allogeneic cell therapies for oncology. CB-010, its lead allogeneic CAR-T cell program, targets CD19 and is being evaluated in a Phase 1 clinical trial for patients with relapsed/refractory B cell non-Hodgkin lymphoma.

CB-011, Caribous second allogeneic CAR-T cell therapy, targets BCMA for multiple myeloma, while CB-012, Caribous third allogeneic CAR-T cell therapy, targets CD371 for acute myeloid leukemia.

CB-011 and CB-012 are in preclinical development.

Additionally, Caribou is developing iPSC-derived allogeneic natural killer (NK) cell therapies for solid tumors.

See the original post:
AbbVie and Caribou partner on CAR-T cell therapy development - BioPharma-Reporter.com

Due to the unique consequences of the pandemic, we are able to catch a glimpse of a potential future. One where we sit, plugged into our computers, devoid of physical human connection. What will society look like after the pandemic? Will we continue to stay isolated? Surely advancements in technology have played key roles in prolonging our lives, allowing us to continue to work and socialise, but to what end? With these newly emerging technologies are we destined to live forever, in a suspended state, in front of the glow of our 4k computer screens? Will gene editing technologies be used to keep us alive forever so that we can binge watch infinite Netflix shows, send meaningless emails and scroll through social media feeds?

Q4 2020 hedge fund letters, conferences and more

The Institute of Zoology of the China Academy of Science has successfully prolonged the lives of mice by using CRISPR/Cas 9. CRISPR has become a relatively simple and popular way to edit strands of DNA. The CRISPR/Cas 9 study found a gene tied to cellular senescence (which tells cells to stop growing) and also, that CRISPR/Cas9 treatment can make partially dormant the aging process. CRISPR/Cas9 treatment allowed mice to live 25% longer and be physically stronger. Biologists see these results being relatively easy to reproduce on humans in a clinical setting.

Company managements looking to achieve earnings growth often default to cost cutting, stock buyback, accounting gimmicks and other methods. But there is another way. More often than not, managements overlook pricing as a driver of earnings growth. Pricing power can be an effect way of boosting a company's bottom line. Read More

Existing in a world where individuals are able to receive treatment to live longer borders dystopian science fiction. The treatment can reduce the need for medical attention by potentially reducing injuries, heart attacks, and organ failures.

In part, due to breakthroughs in the tech and science industries, life expectancy in the 21st century is projected to steadily increase. In a study published in the Lancet, average life expectancy is predicted to rise in 35 industrialized countries by 4.4 years in men and women by 2030.

Life expectancy will likely increase as we migrate away from laborer positions. Currently, the National Center for Health Statistics puts unintentional accidents, primarily happening within labor positions, as the third leading cause of death in the U.S. Many industrialized countries, like the U.S., have been witness to a slow disappearance of the labor class, but the pandemic has made that increasingly more apparent. Businesses are shifting towards automated technology to replace physical human interactions to curb the spread of Covid-19. Even within agriculture and farming industries, already abundant with machine automation, companies are pushing even further away from human labor in an effort to reduce virus rates.

Simultaneously, we are witness to the emergence of new and remote jobs and work settings. Homes are new sites for schooling, work and entertainment. Before the pandemic there was already a struggle to maintain a separation between home and work identities. The pandemic has exacerbated this problem. How do we find rest and recuperation when we are living within the office space? Time on the job stretches on forever as we receive work emails while watching Netflix with our families. If life expectancy in humans gets extended by using CRISPR/Cas 9 are we just creating our own version of purgatory? Is our future one where our time working stretches on seemingly infinitely while we simultaneously cease to age? Are we becoming the perfect machine, one that is held together by technological advancements that inadvertently disembody and dehumanise us?

Was society slowly transitioning toward isolation before the pandemic? Is isolation a byproduct of neoliberalism? Gated communities, mass incarceration, office cubicles, segregation in neighborhoods, retirement homes, hospitals, national borders and private properties all verify how neoliberalism operates. Now we are being asked to isolate within the confines of our homes. When the pandemic is over, will people continue to order food, work, shop and socialise from isolated and often virtual spaces or will we be able to shift back into the more public and physical? Will the last remaining physical laborers, those that are delivering goods to doorsteps, be replaced by driverless vehicles?

About the Author

Matthew Bacher is an author and professional artist and is working towards his MFA in Painting and Printmaking at San Diego State University. His work deals with postmodern ideas around nature, technology and the self. You can find his artwork atmbacherart.com.

More:
CRISPR Treatment Offers The Potential To Live Forever - ValueWalk

The term genome generally refers to the entire sequence of DNA of an organism. The genome includes genes: sequences of DNA with specific functions that are involved in the production of the proteins needed to carry out many biological roles. Genome editing is the deliberate alteration of a selected DNA sequence in a living cell. A strand of DNA is cut at a specific point and naturally existing cellular repair mechanisms, then fix the broken DNA strands.

The Australia Gene Editing market 2021 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Australia Gene Editing market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Get a free sample report of this Market now! @ https://www.reportconsultant.com/request_sample.php?id=47058

Top Vendors of Australia Gene Editing Market:-

CRISPR Therapeutics, Thermo Fisher Scientific, GenScript Corporation, Merck KgaA, Sangamo Therapeutics, Inc., Horizon Discovery Group, Integrated DNA Technologies, New England Biolabs, OriGene Technologies, Lonza Group, and Editas Medicine.

Australia Gene Editing Market, By Application

Australia Gene Editing Market, By Technology

Australia Gene Editing Market, By End-user:

This report is available up to 40% discount for a limited time only: @ https://www.reportconsultant.com/ask_for_discount.php?id=47058

The study is a source of reliable data on:

-Key market segments and sub-segments

-Evolving market trends and dynamics

-Changing supply and demand scenarios

-Quantifying market opportunities through market sizing and market forecasting

-Tracking current trends/opportunities/challenges

-Competitive insights

-Opportunity mapping in terms of technological breakthroughs

The Australia Gene Editing market research report completely covers the vital statistics of the capacity, Development, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs.

Fundamentals of Table of Content:

About us:

Report Consultant A worldwide pacesetter in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly by taking calculative risks leading to lucrative businesses in the ever-changing market. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies.

Our research reports will give you the most realistic and incomparable experience of revolutionary market solutions. We have effectively steered businesses all over the world through our market research reports with our predictive nature and are exceptionally positioned to lead digital transformations. Thus, we craft greater value for clients by presenting progressive opportunities in the futuristic market.

Contact us:

Riaana Singh

(Report Consultant)

Contact No: +81-368444299

sales@reportconsultant.com

http://www.reportconsultant.com

See the rest here:
Australia Gene Editing Market to Garner Astonishing CAGR by 2028 with Top Key Players: CRISPR Therapeutics, Thermo Fisher Scientific, GenScript...

Chinese scientists have successfully prolonged the lives of mice by using CRISPR.

Stay informed and join our daily newsletter now!

February10, 20214 min read

Due to the unique consequences of the pandemic, we are able to catch a glimpse of a potential future. One where we sit, plugged into our computers, devoid of physical human connection. What will society look like after thepandemic? Will we continue to stay isolated? Surely advancements in technology have played key roles in prolonging our lives, allowing us to continue to work and socialise, but to what end? With these newly emerging technologies are we destined to live forever, in a suspended state, in front of the glow of our 4k computer screens? Will gene editing technologies be used to keep us alive forever so that we can binge watch infinite Netflix shows, send meaningless emails and scroll through social media feeds?

The Institute of Zoology of the China Academy of Science has successfully prolonged the lives of mice by using CRISPR/Cas 9. CRISPR has become a relatively simple and popular way to edit strands of DNA. The CRISPR/Cas 9 study found a gene tied to cellular senescence (which tells cells to stop growing) and also, that CRISPR/Cas9 treatment can make partially dormant theagingprocess. CRISPR/Cas9 treatment allowed mice to live 25% longer and be physically stronger. Biologists see these results being relatively easy to reproduce on humans in a clinical setting.

Existing in a world where individuals are able to receive treatment to live longer borders dystopian science fiction. The treatment can reduce the need for medical attention by potentially reducing injuries, heart attacks, and organ failures.

In part, due to breakthroughs in the tech and science industries, life expectancy in the 21st century is projected to steadily increase. In a study published in the Lancet, average life expectancy is predicted to rise in 35 industrialized countries by 4.4 years in men and women by 2030.

Life expectancy will likely increase as we migrate away from laborer positions. Currently, the National Center for Health Statistics puts unintentional accidents, primarily happening within labor positions, as the third leading cause of death in the U.S. Many industrialized countries, like the U.S., have been witness to a slow disappearance of the labor class, but the pandemic has made that increasingly more apparent. Businesses are shifting towards automated technology to replace physical human interactions to curb the spread of Covid-19. Even within agriculture andfarmingindustries, already abundant with machine automation, companies are pushing even further away from human labor in an effort to reduce virus rates.

Simultaneously, we are witness to the emergence of new and remote jobs and work settings.Homesare new sites for schooling, work, andentertainment. Before the pandemic, there was already a struggle to maintain a separation between home and work identities. The pandemic has exacerbated this problem. How do we find rest and recuperation when we are living within the office space? Time on the job stretches on forever as we receive work emails while watching Netflix with our families. If life expectancy in humans gets extended by using CRISPR/Cas 9 are we just creating our own version of purgatory? Is our future one where our time working stretches on seemingly infinitely while we simultaneously cease to age? Are we becoming the perfect machine, one that is held together by technological advancements that inadvertently disembody and dehumanize us?

Was society slowly transitioning toward isolation before the pandemic? Is isolation a byproduct of neoliberalism? Gated communities, mass incarceration, office cubicles, segregation in neighborhoods,retirementhomes, hospitals, national borders and private properties all verify how neoliberalism operates. Now we are being asked to isolate ourselves within the confines of our homes. When the pandemic is over, will people continue to order food, work, shop, and socialize from isolated and often virtual spaces or will we be able to shift back into the more public and physical? Will the last remaining physical laborers, those that are delivering goods to doorsteps, be replaced by driverless vehicles?

Here is the original post:
CRISPR Offers the Potential to Live Forever, But to What End? - Entrepreneur

TipRanks

Lets talk about growth. With corona receding, politics growing less exciting, and a new year ahead, investors are getting optimistic and that means theres a hunt for stocks that will bring in strong returns. In other words, growth stocks. In a recent interview, Jan Hatzius, chief economist at investment giant Goldman Sachs, said that he sees GDP growth in 2Q21 hitting as high as 10%. In an environment like that, most stocks are going to show a growth trend. Now, we all know that past performance wont guarantee future results. Still, the best place to start looking for tomorrows high-growth stocks is among yesterdays winners. Bearing this in mind, we set out to find stocks flagged as exciting growth plays by Wall Street. Using TipRanks database, we locked in on three analyst-backed names that have already notched impressive gains and boast solid growth narratives for the long-term. Kaleyra (KLR) We will start with Kaleyra, a cloud computing company offering communications solutions. The companys SaaS platform supports SMS, voice calls, and chatbots a product with obvious applications and value in todays office climate, with the strong push to telecommuting and remote work. Kaleyra boasts over 3,500 customers, who make 3 billion voice calls and sent 27 billion text messages in 2019 (the last year with full numbers available). Over the past 6 months, KLR shares have shown tremendous growth, appreciating 155%. Kaleyras revenues have grown along with the share value. The companys 3Q20 results hit $38.3 million, the best since KLR went public. While Kaleyra still runs a net earnings loss each quarter, the Q3 EPS was the lowest such loss in the past four quarters. Maxim analyst Allen Klee is bullish on KLR, seeing recent growth and product offerings as indicative of future performance. Over the past few years, Kaleyra has posted double-digit revenue growth and positive adjusted EBITDA. We forecast revenue growth of 9%, 22%, and 28% for 2020-2022. We project adjusted EBITDA declines in 2020 to reflect public company costs and COVID-19, but growth at over twice the rate of revenue for the following two years. We expect benefits from operating leverage, low-cost tech employees, cost volume discounts as the company expands, and margin improvement from new offerings and geographies. Over the longer term, we believe the company can grow revenue close to 30% with even faster bottom line growth," Klee opined. With such growth, its no wonder Klee takes a bullish stance on KLR. To kick off his coverage, the analyst published a Buy rating and set a $22 price target. This figure implies a 45% for the coming year. (To watch Klees track record, click here) Overall, based on the 3 Buy ratings vs no Holds or Sells assigned in the last three months, Wall Street analysts agree that this Strong Buy is a solid bet. It also doesnt hurt that its $19 average price target implies ~26% upside potential. (See KLR stock analysis on TipRanks) Vista Outdoor (VSTO) Next up, Vista Outdoor, is a venerable company that saw its niche gain attractiveness in recent times. Vista is a sporting goods company, with 40 brands in two main divisions: outdoor products and shooting sports. Vistas brands include well-known names as Bushnell Golf, CamelBak, and Remington. The company has found a burst of success in the corona year as people have turned more and more to outdoor activities that can be practiced solo or in small groups expanding the customer base. VSTO shares are up as a result, by 214% in the last 12 months. Vistas earnings reflect the increase in consumer interest in outdoor sports. The companys EPS grew in 2020, turning from a net loss to a $1.34 per share profit in the fiscal Q2 report (released in November). The fiscal Q3 report, released earlier this month, showed lower earnings, at $1.31 per share, but was still considered solid by the company, as it covered winter months when the company normally sees a revenue decline. Both quarters showed strong year-over-year EPS gains. Covering Vista for B. Riley, 5-star analyst Eric Wold sees several avenues for continued growth by Vista. He is impressed by the growth in firearm and ammunition sales, and by the price increase for products in both the outdoor goods and the shooting sports divisions. Given our expectation that the increased industry participation numbers for both outdoor products and shooting sports during the pandemic will represent an incremental tailwind for VSTO in the coming years beyond the impressive production visibility that has been created by depleted channel inventory levels, we continue to see an attractive set-up for baseline growth, Wold commented. Overall, Wold is bullish on the stock and rates it a Buy, with a $41 price target. This figure indicates room for 27% upside in the coming year. (To watch Wolds track record, click here) Vista is another company with a unanimous Strong Buy consensus rating. That rating is based on 9 recent reviews, all to Buy. VSTO shares have an average price target of $36.78, which gives an upside of 14% from the trading price of $32.15. (See VSTO stock analysis on TipRanks) Textainer Group Holdings (TGH) You might not think about the ubiquitous cargo container, but these deceptively simple metal boxes have changed the face of bulk transport since their breakout proliferation in the 1960s. These containers make it easy to organize, load, ship, and track vast amounts of cargo, and are especially valuable for their ease of switching; containers can be quickly loaded on or switched between ships, trains, and trucks. Textainer is a billion-dollar company that buys, owns, and leases shipping containers for the cargo industry. The company has over 250 customers, and boasts a fleet of 3 million twenty-foot equivalent units (TEUs). Textainer is also a major reseller of used containers, and operates from 500 depots around the world. Even during the corona pandemic, when international trading routes and patterns were badly disrupted, and the quarterly revenues were down year-over-year, Textainer saw share gains. The companys stock soared 110% over the past 12 months. The bulk of these gains have come in the past six months, as economies and trading patterns have begun to reopen. Looking at Textainer for B. Riley, analyst Daniel Day is deeply impressed. He sees this company as the lowest priced among its peer group, with a strong market share in a competitive industry. Day rates TGH a Buy, and his $31 price target suggests it has room for 57% growth ahead of it. In support of this bullish stance, Day writes, in part, We believe that TGH is an underfollowed, misunderstood name that is ideal for the portfolio of a deep value investor looking for cash flowgenerative names trading at a steep discount to intrinsic value. With new container prices at multiyear highs amid a resurgence in container shipping, we expect upcoming earnings results to be positive catalyst events for TGH Some stocks fly under the radar, and TGH is one of those. Day's is the only recent analyst review of this company, and it is decidedly positive. (See TGH stock analysis on TipRanks) To find good ideas for growth stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

See the article here:
Global CRISPR Gene Editing Market (2020 to 2030) - Focus on Products, Applications, End-users, Country Data and Competitive Landscape -...

Dublin, Feb. 08, 2021 (GLOBE NEWSWIRE) -- The "Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to reach $10,825.1 million by 2030, registering a CAGR of 26.86% during the forecast.

The development of genome engineering with potential applications proved to reflect a remarkable impact on the future of the healthcare and life science industry. The high efficiency of the CRISPR-Cas9 system has been demonstrated in various studies for genome editing, which resulted in significant investments within the field of genome engineering. However, there are several limitations, which need consideration before clinical applications. Further, many researchers are working on the limitations of CRISPR gene editing technology for better results. The potential of CRISPR gene editing to alter the human genome and modify the disease conditions is incredible but exists with ethical and social concerns.

The growth is attributed to the increasing demand in the food industry for better products with improved quality and nutrient enrichment and the pharmaceutical industry for targeted treatment for various diseases. Further, the continued significant investments by healthcare companies to meet the industry demand and growing prominence for the gene therapy procedures with less turnaround time are the prominent factors propelling the growth of the global CRISPR gene editing market.

Research organizations, pharmaceutical and biotechnology industries, and institutes are looking for more efficient genome editing technologies to increase the specificity and cost-effectiveness, also to reduce turnaround time and human errors. Further, the evolution of genome editing technologies has enabled wide range of applications in various fields, such as industrial biotech and agricultural research. These advanced methods are simple, super-efficient, cost-effective, provide multiplexing, and high throughput capabilities. The increase in the geriatric population and increasing number of cancer cases, and genetic disorders across the globe are expected to translate into significantly higher demand for CRISPR gene editing market.

Furthermore, the companies are investing huge amounts in the research and development of CRISPR gene editing products, and gene therapies. The clinical trial landscape of various genetic and chronic diseases has been on the rise in recent years, and this will fuel the CRISPR gene editing market in the future.

Within the research report, the market is segmented based on product type, application, end-user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Key Companies Profiled

Abcam, Inc., Applied StemCell, Inc., Agilent Technologies, Inc., Cellecta, Inc., CRISPR Therapeutics AG, Thermo Fisher Scientific, Inc., GeneCopoeia, Inc., GeneScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Merck KGaA, New England Biolabs, Inc., Origene Technologies, Inc., Rockland Immunochemicals, Inc., Synthego Corporation, System Biosciences LLC, ToolGen, Inc., Takara Bio

Key Questions Answered in this Report:

Key Topics Covered:

1 Technology Definition

2 Research Scope

3 Research Methodology

4 Market Overview4.1 Introduction4.2 CRISPR Gene Editing Market Approach4.3 Milestones in CRISPR Gene Editing4.4 CRISPR Gene Editing: Delivery Systems4.5 CRISPR Technology: A Potential Tool for Gene Editing4.6 CRISPR Gene Editing Current Scenario4.7 CRISPR Gene Editing Market: Future Potential Application Areas

5 Global CRISPR Gene Editing Market, $Million, 2020-20305.1 Pipeline Analysis5.2 CRISPR Gene Editing Market and Growth Potential, 2020-20305.3 Impact of COVID-19 on CRISPR Gene Editing Market5.3.1 Impact of COVID-19 on Global CRISPR Gene Editing Market Growth Rate5.3.1. Impact on CRISPR Gene Editing Companies5.3.2 Clinical Trial Disruptions and Resumptions5.3.3 Application of CRISPR Gene Editing in COVID-19

6 Market Dynamics6.1 Impact Analysis6.2 Market Drivers6.2.1 Prevalence of Genetic Disorders and Use of Genome Editing6.2.2 Government and Private Funding6.2.3 Technology Advancement in CRISPR Gene Editing6.3 Market Restraints6.3.1 CRISPR Gene Editing: Off Target Effects and Delivery6.3.2 Ethical Concerns and Implications With Respect to Human Genome Editing6.4 Market Opportunities6.4.1 Expanding Gene and Cell Therapy Area6.4.2 CRISPR Gene Editing Scope in Agriculture

7 Industry Insights7.1 Introduction7.2 Funding Scenario7.3 Regulatory Scenario of CRISPR Gene Editing Market7.4 Pricing of CRISPR Gene Editing7.5 Reimbursement of CRISPR Gene Editing7.5.1 CRISPR Gene Editing: Insurance Coverage in the U.S.

8 CRISPR Gene Editing Patent Landscape8.1 Overview8.2 CRISPR Gene Editing Market Patent Landscape: By Application8.3 CRISPR Gene Editing Market Patent Landscape: By Region8.4 CRISPR Gene Editing Market Patent Landscape: By Year

9 Global CRISPR Gene Editing Market (by Product Type), $Million9.1 Overview9.2 CRISPR Products9.2.1 Kits and Enzymes9.2.1.1 Vector-Based Cas99.2.1.2 DNA-Free Cas99.2.2 Libraries9.2.3 Design Tools9.2.4 Antibodies9.2.5 Other Products9.3 CRISPR Services9.3.1 gRNA Design and Vector Construction9.3.2 Cell Line and Engineering9.3.3 Screening Services9.3.4 Other Services

10 CRISPR Gene Editing Market (by Application), $Million10.1 Overview10.2 Agriculture10.3 Biomedical10.3.1 Gene Therapy10.3.2 Drug Discovery10.3.3 Diagnostics10.4 Industrial10.5 Other Applications

11 Global CRISPR Gene Editing Market (by End User)11.1 Academic Institutions and Research Centers11.2 Biotechnology Companies11.3 Contract Research Organizations (CROs)11.4 Pharmaceutical and Biopharmaceutical Companies

12 Global CRISPR Gene Editing Market (by Region)12.1 Introduction12.2 North America12.3 Europe12.4 Asia-Pacific12.5 Latin America

13 Competitive Landscape13.1 Key Developments and Strategies13.1.1 Overview13.1.1.1 Regulatory and Legal Developments13.1.1.2 Synergistic Activities13.1.1.3 M&A Activities13.1.1.4 Funding Activities13.2 Market Share Analysis13.3 Growth Share Analysis

14 Company Profiles14.1 Overview14.2 Abcam, Inc.14.2.1 Company Overview14.2.2 Role of Abcam, Inc. in the Global CRISPR Gene Editing Market14.2.3 Financials14.2.4 SWOT Analysis14.3 Applied StemCell, Inc.14.3.1 Company Overview14.3.2 Role of Applied StemCell, Inc. in the Global CRISPR Gene Editing Market14.3.3 SWOT Analysis14.4 Agilent Technologies, Inc.14.4.1 Company Overview14.4.2 Role of Agilent Technologies, Inc. in the Global CRISPR Gene Editing Market14.4.3 Financials14.4.4 R&D Expenditure, 2017-201914.4.5 SWOT Analysis14.5 Cellecta, Inc.14.5.1 Company Overview14.5.2 Role of Cellecta, Inc. in the Global CRISPR Gene Editing Market14.5.3 SWOT Analysis14.6 CRISPR Therapeutics AG14.6.1 Company Overview14.6.2 Role of CRISPR Therapeutics AG in the Global CRISPR Gene Editing Market14.6.3 Financials14.6.4 R&D Expenditure, 2017-201914.6.5 SWOT Analysis14.7 Thermo Fisher Scientific, Inc. INC14.7.1 Company Overview14.7.2 Role of Thermo Fisher Scientific, Inc. in the Global CRISPR Gene Editing Market14.7.3 Financials14.7.4 R&D Expenditure, 2017-201914.7.5 SWOT Analysis14.8 GeneCopoeia, Inc.14.8.1 Company Overview14.8.2 Role of GeneCopoeia, Inc. in the Global CRISPR Gene Editing Market14.8.3 SWOT Analysis14.9 GeneScript Biotech Corporation14.9.1 Company Overview14.9.2 Role of GenScript Biotech in the Global CRISPR Gene Editing Market14.9.3 Financials14.9.4 SWOT Analysis14.1 Horizon Discovery Group PLC14.10.1 Company Overview14.10.2 Role of Horizon Discovery Group PLC in the Global CRISPR Gene Editing Market14.10.3 Financials14.10.4 SWOT Analysis14.11 Integrated DNA Technologies, Inc.14.11.1 Company Overview14.11.2 Role of Integrated DNA Technologies, Inc. in the Global CRISPR Gene Editing Market14.11.3 SWOT Analysis14.12 Merck KGaA14.12.1 Company Overview14.12.2 Role of Merck KGaA in the Global CRISPR Gene Editing Market14.12.3 Financials14.12.4 SWOT Analysis14.13 New England Biolabs, Inc.14.13.1 Company Overview14.13.2 Role of Integrated DNA Technologies, Inc. in the Global CRISPR Gene Editing Market14.13.3 SWOT Analysis14.14 Origene Technologies, Inc.14.14.1 Company Overview14.14.2 Role of Origene Technologies, Inc. in the Global CRISPR Gene Editing Market14.14.3 SWOT Analysis14.15 Rockland Immunochemicals, Inc.14.15.1 Company Overview14.15.2 Role of Rockland Immunochemicals, Inc. in the Global CRISPR Gene Editing Market14.15.3 SWOT Analysis14.16 Synthego Corporation14.16.1 Company Overview14.16.2 Role of Synthego Corporation in the Global CRISPR Gene Editing Market14.16.3 SWOT Analysis14.17 System Biosciences LLC14.17.1 Company Overview14.17.2 Role of System Biosciences LLC in the Global CRISPR Gene Editing Market14.17.3 SWOT Analysis14.18 ToolGen, Inc.14.18.1 Company Overview14.18.2 Role of ToolGen, Inc. in the Global CRISPR Gene Editing Market14.18.3 SWOT Analysis14.19 Takara Bio14.19.1 Company Overview14.19.2 Role of Takara Bio in the Global CRISPR Gene Editing Market14.19.3 Financials14.19.4 SWOT Analysis

For more information about this report visit https://www.researchandmarkets.com/r/c7om7t

See more here:
Outlook on the CRISPR Gene Editing Global Market to 2030 - Analysis and Forecasts - GlobeNewswire

TipRanks

Lets talk about growth. With corona receding, politics growing less exciting, and a new year ahead, investors are getting optimistic and that means theres a hunt for stocks that will bring in strong returns. In other words, growth stocks. In a recent interview, Jan Hatzius, chief economist at investment giant Goldman Sachs, said that he sees GDP growth in 2Q21 hitting as high as 10%. In an environment like that, most stocks are going to show a growth trend. Now, we all know that past performance wont guarantee future results. Still, the best place to start looking for tomorrows high-growth stocks is among yesterdays winners. Bearing this in mind, we set out to find stocks flagged as exciting growth plays by Wall Street. Using TipRanks database, we locked in on three analyst-backed names that have already notched impressive gains and boast solid growth narratives for the long-term. Kaleyra (KLR) We will start with Kaleyra, a cloud computing company offering communications solutions. The companys SaaS platform supports SMS, voice calls, and chatbots a product with obvious applications and value in todays office climate, with the strong push to telecommuting and remote work. Kaleyra boasts over 3,500 customers, who make 3 billion voice calls and sent 27 billion text messages in 2019 (the last year with full numbers available). Over the past 6 months, KLR shares have shown tremendous growth, appreciating 155%. Kaleyras revenues have grown along with the share value. The companys 3Q20 results hit $38.3 million, the best since KLR went public. While Kaleyra still runs a net earnings loss each quarter, the Q3 EPS was the lowest such loss in the past four quarters. Maxim analyst Allen Klee is bullish on KLR, seeing recent growth and product offerings as indicative of future performance. Over the past few years, Kaleyra has posted double-digit revenue growth and positive adjusted EBITDA. We forecast revenue growth of 9%, 22%, and 28% for 2020-2022. We project adjusted EBITDA declines in 2020 to reflect public company costs and COVID-19, but growth at over twice the rate of revenue for the following two years. We expect benefits from operating leverage, low-cost tech employees, cost volume discounts as the company expands, and margin improvement from new offerings and geographies. Over the longer term, we believe the company can grow revenue close to 30% with even faster bottom line growth," Klee opined. With such growth, its no wonder Klee takes a bullish stance on KLR. To kick off his coverage, the analyst published a Buy rating and set a $22 price target. This figure implies a 45% for the coming year. (To watch Klees track record, click here) Overall, based on the 3 Buy ratings vs no Holds or Sells assigned in the last three months, Wall Street analysts agree that this Strong Buy is a solid bet. It also doesnt hurt that its $19 average price target implies ~26% upside potential. (See KLR stock analysis on TipRanks) Vista Outdoor (VSTO) Next up, Vista Outdoor, is a venerable company that saw its niche gain attractiveness in recent times. Vista is a sporting goods company, with 40 brands in two main divisions: outdoor products and shooting sports. Vistas brands include well-known names as Bushnell Golf, CamelBak, and Remington. The company has found a burst of success in the corona year as people have turned more and more to outdoor activities that can be practiced solo or in small groups expanding the customer base. VSTO shares are up as a result, by 214% in the last 12 months. Vistas earnings reflect the increase in consumer interest in outdoor sports. The companys EPS grew in 2020, turning from a net loss to a $1.34 per share profit in the fiscal Q2 report (released in November). The fiscal Q3 report, released earlier this month, showed lower earnings, at $1.31 per share, but was still considered solid by the company, as it covered winter months when the company normally sees a revenue decline. Both quarters showed strong year-over-year EPS gains. Covering Vista for B. Riley, 5-star analyst Eric Wold sees several avenues for continued growth by Vista. He is impressed by the growth in firearm and ammunition sales, and by the price increase for products in both the outdoor goods and the shooting sports divisions. Given our expectation that the increased industry participation numbers for both outdoor products and shooting sports during the pandemic will represent an incremental tailwind for VSTO in the coming years beyond the impressive production visibility that has been created by depleted channel inventory levels, we continue to see an attractive set-up for baseline growth, Wold commented. Overall, Wold is bullish on the stock and rates it a Buy, with a $41 price target. This figure indicates room for 27% upside in the coming year. (To watch Wolds track record, click here) Vista is another company with a unanimous Strong Buy consensus rating. That rating is based on 9 recent reviews, all to Buy. VSTO shares have an average price target of $36.78, which gives an upside of 14% from the trading price of $32.15. (See VSTO stock analysis on TipRanks) Textainer Group Holdings (TGH) You might not think about the ubiquitous cargo container, but these deceptively simple metal boxes have changed the face of bulk transport since their breakout proliferation in the 1960s. These containers make it easy to organize, load, ship, and track vast amounts of cargo, and are especially valuable for their ease of switching; containers can be quickly loaded on or switched between ships, trains, and trucks. Textainer is a billion-dollar company that buys, owns, and leases shipping containers for the cargo industry. The company has over 250 customers, and boasts a fleet of 3 million twenty-foot equivalent units (TEUs). Textainer is also a major reseller of used containers, and operates from 500 depots around the world. Even during the corona pandemic, when international trading routes and patterns were badly disrupted, and the quarterly revenues were down year-over-year, Textainer saw share gains. The companys stock soared 110% over the past 12 months. The bulk of these gains have come in the past six months, as economies and trading patterns have begun to reopen. Looking at Textainer for B. Riley, analyst Daniel Day is deeply impressed. He sees this company as the lowest priced among its peer group, with a strong market share in a competitive industry. Day rates TGH a Buy, and his $31 price target suggests it has room for 57% growth ahead of it. In support of this bullish stance, Day writes, in part, We believe that TGH is an underfollowed, misunderstood name that is ideal for the portfolio of a deep value investor looking for cash flowgenerative names trading at a steep discount to intrinsic value. With new container prices at multiyear highs amid a resurgence in container shipping, we expect upcoming earnings results to be positive catalyst events for TGH Some stocks fly under the radar, and TGH is one of those. Day's is the only recent analyst review of this company, and it is decidedly positive. (See TGH stock analysis on TipRanks) To find good ideas for growth stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Originally posted here:
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day - Yahoo Finance

The study on the global CRISPR and CAS Gene market defines all of the segments together with the market sizing, year-over-year evaluation, and shape and size of the enterprise. Along with those product applications, it also examined whether it reaches up to the end-users or not. This report on this CRISPR and CAS Gene market has given an overall view of the recent technologies used and technological improvements. It also focuses on recent industry trends and which products are quite demanding from a customers perspective.

This report is representing a whole market scenario on a global basis. In this report, we can also find the analysis growth of industries. Through this report, we can easily interpreter the level of market competition, different pricing models, the latest market trends, customer demand, etc. This report acknowledges the revenue model and market expansion of this CRISPR and CAS Gene market. If you want to get that full market information, then this report can help you. It also gives a comprehensive knowledge about the demand and supply graph. Suppose that demand curves moved downward, then from this report, you can know about those factors responsible for its decline.

>>>Get a Sample Copy of the Report at https://www.coherentmarketinsights.com/insight/request-sample/2598

CRISPR and CAS Gene market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level). Details included are company description, major business, company total revenue and the sales, revenue generated in CRISPR and CAS Gene business, the date to enter into the CRISPR and CAS Gene market, CRISPR and CAS Gene product introduction, recent developments, etc.

Some of the key players/Manufacturers involved in the CRISPR and CAS Gene MarketCaribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.

Detailed Segmentation:

By Product Type:

By Application:

By End User:

Get up to 30% Discount on this Premium Report @:https://www.coherentmarketinsights.com/insight/request-discount/2598

If opting for the Global version of CRISPR and CAS Gene Market analysis is provided for major regions as follows:

North America (The US, Canada, and Mexico)

Europe (the UK, Germany, France, and Rest of Europe)

Asia Pacific (China, India, and Rest of Asia Pacific)

Latin America (Brazil and Rest of Latin America)

Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)

Research and Methodology

For the research, the CRISPR and CAS Gene markets research teams are adopted various high-end techniques. Industry best analysts are worked on this report. They collected data from various reliable sources and have taken samples of different market segments. They utilize both qualitative and quantitative data in this report. All data are based on primary sources, which are focused on the assessment year 2020-2027. For wise decision-making, they have also done SWOT analysis, which can also help them know their predicted future results. This report also helps to develop CRISPR and CAS Gene market growth by improvising its strategic models.

Key Benefits:

This study gives a detailed analysis of drivers and factors limiting the market expansion of CRISPR and CAS Gene

The micro-level analysis is conducted based on its product types, end-user applications, and geographies

Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this CRISPR and CAS Gene market

Apply Promo Code STAYHOME andGet Up to 30%Discount

If you purchase the report this year:

Buy This Complete A Business Report:https://www.coherentmarketinsights.com/insight/buy-now/2598

Table of Contents

Report Overview: It includes the CRISPR and CAS Gene market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about CRISPR and CAS Gene market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the CRISPR and CAS Gene market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the CRISPR and CAS Gene market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Phone: US +1-206-701-6702/UK +44-020 8133 4027Email:sales@coherentmarketinsights.com

Original post:
CRISPR and CAS Gene Market Competitive Insights With Global Outlook 2020-2027 | Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas...

New York, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" - https://www.reportlinker.com/p06018975/?utm_source=GNW Application Agricultural, Biomedical (Gene Therapy, Drug Discovery, And Diagnostics), Industrial, and Other Applications [Genetically Modified Foods (GM Foods), Biofuel, And Animal (Livestock) Breeding] End-User - Academic Institutes and Research Centers, Biotechnology Companies, Contract Research Organizations (CROs), and Pharmaceutical and Biopharmaceutical Companies

Regional Segmentation

North America U.S., Canada Europe Germany, France, Italy, U.K., Spain, Switzerland, and Rest-of-Europe Asia-Pacific China, Japan, India, South Korea, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC) Latin America Brazil, Mexico, and Rest-of-the-Latin America Rest-of-the-World

Growth Drivers

Prevalence of Genetic Disorders and Use of Genome Editing Government and Private Funding Technology Advancement in CRISPR Gene Editing

Market Restraints

CRISPR Gene Editing: Off Target Effects and Delivery Ethical Concerns and Implications with Respect to Human Genome Editing

Market Opportunities

Expanding Gene and Cell Therapy Area CRISPR Gene Editing Scope in Agriculture

Key Companies ProfiledAbcam, Inc., Applied StemCell, Inc., Agilent Technologies, Inc., Cellecta, Inc., CRISPR Therapeutics AG, Thermo Fisher Scientific, Inc., GeneCopoeia, Inc., GeneScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Merck KGaA, New England Biolabs, Inc., Origene Technologies, Inc., Rockland Immunochemicals, Inc., Synthego Corporation, System Biosciences LLC, ToolGen, Inc., Takara Bio

Key Questions Answered in this Report: What is CRISPR gene editing? What is the timeline for the development of CRISPR technology? How did the CRISPR gene editing market evolve, and what is its scope in the future? What are the major market drivers, restraints, and opportunities in the global CRISPR gene editing market? What are the key developmental strategies that are being implemented by the key players to sustain this market? What is the patent landscape of this market? What will be the impact of patent expiry on this market? What is the impact of COVID-19 on this market? What are the guidelines implemented by different government bodies to regulate the approval of CRISPR products/therapies? How is CRISPR gene editing being utilized for the development of therapeutics? How will the investments by public and private companies and government organizations affect the global CRISPR gene editing market? What was the market size of the leading segments and sub-segments of the global CRISPR gene editing market in 2019? How will the industry evolve during the forecast period 2020-2030? What will be the growth rate of the CRISPR gene editing market during the forecast period? How will each of the segments of the global CRISPR gene editing market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2030? Which product segment and application segment are expected to register the highest CAGR for the global CRISPR gene editing market? What are the major benefits of the implementation of CRISPR gene editing in different field of applications including biomedical research, agricultural research, industrial research, gene therapy, drug discovery, and diagnostics? What is the market size of the CRISPR gene editing market in different countries of the world? Which geographical region is expected to contribute to the highest sales of CRISPR gene editing market? What are the reimbursement scenario and regulatory structure for the CRISPR gene editing market in different regions? What are the key strategies incorporated by the players of global CRISPR gene editing market to sustain the competition and retain their supremacy?

Market OverviewThe development of genome engineering with potential applications proved to reflect a remarkable impact on the future of the healthcare and life science industry.The high efficiency of the CRISPR-Cas9 system has been demonstrated in various studies for genome editing, which resulted in significant investments within the field of genome engineering.

However, there are several limitations, which need consideration before clinical applications.Further, many researchers are working on the limitations of CRISPR gene editing technology for better results.

The potential of CRISPR gene editing to alter the human genome and modify the disease conditions is incredible but exists with ethical and social concerns. The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to reach $10,825.1 million by 2030, registering a CAGR of 26.86% during the forecast.

The growth is attributed to the increasing demand in the food industry for better products with improved quality and nutrient enrichment and the pharmaceutical industry for targeted treatment for various diseases. Further, the continued significant investments by healthcare companies to meet the industry demand and growing prominence for the gene therapy procedures with less turnaround time are the prominent factors propelling the growth of the global CRISPR gene editing market.

Research organizations, pharmaceutical and biotechnology industries, and institutes are looking for more efficient genome editing technologies to increase the specificity and cost-effectiveness, also to reduce turnaround time and human errors.Further, the evolution of genome editing technologies has enabled wide range of applications in various fields, such as industrial biotech and agricultural research.

These advanced methods are simple, super-efficient, cost-effective, provide multiplexing, and high throughput capabilities. The increase in the geriatric population and increasing number of cancer cases, and genetic disorders across the globe are expected to translate into significantly higher demand for CRISPR gene editing market.

Furthermore, the companies are investing huge amounts in the research and development of CRISPR gene editing products, and gene therapies. The clinical trial landscape of various genetic and chronic diseases has been on the rise in recent years, and this will fuel the CRISPR gene editing market in the future.

Within the research report, the market is segmented based on product type, application, end-user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive LandscapeThe exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel CRISPR gene editing. Due to the diverse product portfolio and intense market penetration, Merck KGaA, and Thermo Fisher Scientific Inc. have been the pioneers in this field and have been the major competitors in this market. The other major contributors of the market include companies such as Integrated DNA Technologies (IDT), Genscript Biotech Corporation, Takara Bio Inc, Agilent Technologies, Inc., and New England Biolabs, Inc.

Based on region, North America holds the largest share of CRISPR gene editing market due to substantial investments made by biotechnology and pharmaceutical companies, improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

Countries Covered North America U.S. Canada Europe Germany Italy France Spain U.K. Switzerland Rest-of-Europe Asia-Pacific China India Australia South Korea Singapore Japan Rest-of-Asia-Pacific Latin America Brazil Mexico Rest-of-Latin America Rest-of-the-WordRead the full report: https://www.reportlinker.com/p06018975/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read more from the original source:
Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and...

Gene Editing Tools Marketresearch report is the new statistical data source added byA2Z Market Research.

Gene Editing Tools Marketresearch is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis. It also provides market information in terms of development and its capacities.

Get Sample Copy of this report with latest Industry Trend and COVID-19 Impact @:

https://www.a2zmarketresearch.com/sample?reportId=313215

Some of the Top companies Influencing in this Market includes:

Thermofisher Scientific, CRISPR Therapeutics, Editas Medicine, NHGRI, Intellia Therapeutics, Merck KGaA.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Gene Editing Tools market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Gene Editing Tools markets trajectory between forecast periods.

Global Gene Editing Tools Market research report offers:

Key Factors Impacting Market Growth:

Get Up to 30% Discount on the first purchase of this report @:

https://www.a2zmarketresearch.com/discount?reportId=313215

Regions Covered in the Global Gene Editing Tools Market Report 2021:The Middle East and Africa(GCC Countries and Egypt)North America(the United States, Mexico, and Canada)South America(Brazil etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The cost analysis of the Global Gene Editing Tools Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Key questions answered in the report include:

Table of Content (TOC)

Global Gene Editing Tools Market Report 2021 Growth, Trend and Forecast to 2027

Chapter 1 Gene Editing Tools Market Overview

Chapter 2 Global Economic Impact on Gene Editing Tools Industry

Chapter 3 Global Gene Editing Tools Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region (2014-2020)

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions (2014-2020)

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Gene Editing Tools Market Forecast (2021-2027)

Chapter 13 Appendix

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=313215

If you have any special requirements, please let us know and we will offer you the report as you want.

About A2Z Market Research:

The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

Read this article:
Massive Growth of Gene Editing Tools Market 2021 | Size, Demand, Opportunities & Forecast To 2027 | Thermofisher Scientific, CRISPR Therapeutics,...

CRISPR-wielder Mammoth Biosciences will team up with Agilent Technologies to help launch its upcoming COVID-19 diagnostic test, designed to handle more than 4,000 samples per day.

Applying the gene editing technology allows the system to operate much faster than standard PCR-based molecular lab tests, according to Mammoth. The companys CRISPR-based DETECTR assay uses Cas12 enzymes to identify and tag the coronaviruss specific genomic sequences and provides a visual result that can be read by a machine.

The two companies hope to increase the tests throughput speed even more by connecting it with Agilents automated liquid handling systems and sample readers. Dubbed DETECTR BOOST, the platform aims to process about 1,500 samples over an eight-hour shift.

Blazing a Trail to Clinical Trial Diversity: Four-Part Webinar Series from Syneos Health, Featuring Pharma, Clinical Research and Community Health Leaders

This series will identify obstacles that stifle appropriate patient diversity in trials; unpack the organizational overhaul needed; share how sponsors, patients & investigators have come together to overcome hurdles; and explore how policy innovations can move the industry forward.

"A highly-automated workstation for SARS-CoV-2 testing provides the capacity needed to bring routine, robust testing to the broader market, said David Edwards, associate marketing vice president for Agilents mass spectrometry division. By partnering with Mammoth Biosciences, we will be able to provide a simplified workflow that addresses the specific needs of high-throughput clinical testing laboratories.

Similar methods have been explored for COVID-19 tests that can be read with a smartphone camera and a darkened box using fluorescent molecules that produce a faint glow when matched up with the viruss specific genetic material. Prior to the pandemic, the technology was being developed for HIV testing in low-resource areas.

GlaxoSmithKline has also tapped Mammoth to develop a CRISPR-based coronavirus test that could be available over the counter.

More recently, Mammoth announced a contract with MRIGlobal through the U.S. Defense Advanced Research Projects Agency, known as DARPA, to develop CRISPR-based diagnostics and biosurveillance technologies for the Department of Defense. This includes the development of a hand-held device capable of screening for 10 pathogens simultaneously and a lab system that can spot more than 1,000 targets at once.

RELATED: Pairing CRISPR with a smartphone camera, this COVID-19 test finds results in 30 minutes

Co-founded by CRISPR pioneer and Nobel laureate Jennifer Doudna, Ph.D., Mammoth previously received funding support from the National Institutes of Health through its Shark Tank-esque diagnostics competition known as the Rapid Acceleration of Diagnostics initiative, or RADx. The company said it plans to submit its test for an FDA emergency authorization in the near future.

Mammoths mission is to address challenges across healthcare by harnessing the full potential of the CRISPR platform to read and write the code of life," said Mammoths co-founder and CEO, Trevor Martin, Ph.D. This partnership will help address the need for more widespread testing options for COVID-19, helping to fill the gap in the market as testing labs run into supply issues or reach capacity.

Read more here:
Mammoth Biosciences teams with Agilent to deliver CRISPR-based coronavirus tests - FierceBiotech

In recent months, even as our attention has been focused on the coronavirus outbreak, there have been a slew of scientific breakthroughs in treating diseases that cause blindness.

Researchers at U.S.-based Editas Medicine and Ireland-based Allergan have administeredCRISPR for the first time to a person with a genetic disease. This landmark treatment uses the CRISPR approach to a specific mutation in a gene linked to childhood blindness. The mutation affects the functioning of the light-sensing compartment of the eye, called the retina, and leads to loss of the light-sensing cells.

According to the World Health Organization,at least 2.2 billion peoplein the world have some form of visual impairment. In the United States, approximately200,000 people suffer from inherited forms of retinal diseasefor which there is no cure. But things have started to change for good. We can now see light at the end of the tunnel.

I am an ophthalmology and visual sciences researcher, and am particularly interested in these advances becausemy laboratory is focusingon designing new and improved gene therapy approaches to treat inherited forms of blindness.

Gene therapy involves inserting the correct copy of a gene into cells that have a mistake in the genetic sequence of that gene, recovering the normal function of the protein in the cell. The eye is an ideal organ for testing new therapeutic approaches, including CRISPR. That is because the eye is the most exposed part of our brain and thus is easily accessible.

The second reason is that retinal tissue in the eye is shielded from the bodys defense mechanism, which would otherwise consider the injected material used in gene therapy as foreign and mount a defensive attack response. Such a response would destroy the benefits associated with the treatment.

In recent years, breakthrough gene therapy studies paved the way to thefirst ever Food and Drug Administration-approved gene therapy drug, Luxturna TM, for a devastating childhood blindness disease,Leber congenital amaurosisType 2.

This form of Leber congenital amaurosis is caused by mutations in a gene that codes for a protein called RPE65. The protein participates in chemical reactions that are needed to detect light. The mutations lessen or eliminate the function of RPE65, which leads to our inability to detect light blindness.

The treatment method developed simultaneously by groups at University of Pennsylvania and at University College London and Moorefields Eye Hospital involvedinserting a healthy copy of the mutated genedirectly into the space between the retina and the retinal pigmented epithelium, the tissue located behind the retina where the chemical reactions takes place. This gene helped the retinal pigmented epithelium cell produce the missing protein that is dysfunctional in patients.

Although the treated eyes showed vision improvement, as measured by the patients ability to navigate an obstacle course at differing light levels,it is not a permanent fix. This is due to the lack of technologies that can fix the mutated genetic code in the DNA of the cells of the patient.

Lately, scientists have been developing a powerful new tool that is shifting biology and genetic engineering into the next phase. This breakthroughgeneeditingtechnology, which is called CRISPR, enables researchers to directly edit the genetic code of cells in the eye and correct the mutation causing the disease.

Children suffering from the disease Leber congenital amaurosis Type 10 endure progressive vision loss beginning as early as one year old. This specific form of Leber congenital amaurosis is caused by a change to the DNA that affects the ability of the gene called CEP290 to make the complete protein. The loss of the CEP290 protein affects the survival and function of our light-sensing cells, called photoreceptors.

One treatment strategy is to deliver the full form of the CEP290 gene using a virus as the delivery vehicle. But the CEP290 gene is too big to be cargo for viruses. So another approach was needed. One strategy was to fix the mutation by using CRISPR.

The scientists at Editas Medicine first showed safety and proof of the concept of the CRISPR strategy in cells extracted from patient skin biopsy and in nonhuman primate animals.

These studies led to the formulation of thefirst ever in human CRISPR gene therapeutic clinical trial. This Phase 1 and Phase 2 trial will eventually assess the safety and efficacy of the CRISPR therapy in 18 Leber congenital amaurosis Type 10 patients. The patients receive a dose of the therapy while under anesthesia when the retina surgeon uses a scope, needle and syringe to inject the CRISPR enzyme and nucleic acids into the back of the eye near the photoreceptors.

To make sure that the experiment is working and safe for the patients, the clinical trial has recruited people with late-stage disease and no hope of recovering their vision. The doctors are also injecting the CRISPR editing tools into only one eye.

An ongoing project in my laboratory focuses on designing a gene therapy approach for the same gene CEP290. Contrary to the CRISPR approach, which can target only a specific mutation at one time, my team is developing an approach that would work for all CEP290 mutations in Leber congenital amaurosis Type 10.

This approach involves usingshorter yet functional forms of the CEP290 proteinthat can be delivered to the photoreceptors using the viruses approved for clinical use.

Gene therapy that involves CRISPR promises a permanent fix and a significantly reduced recovery period. A downside of the CRISPR approach is the possibility of an off-target effect in which another region of the cells DNA is edited, which could cause undesirable side effects, such as cancer. However, new and improved strategies have made such likelihood very low.

Although the CRISPR study is for a specific mutation in CEP290, I believe the use of CRISPR technology in the body to be exciting and a giant leap. I know this treatment is in an early phase, but it shows clear promise. In my mind, as well as the minds of many other scientists, CRISPR-mediated therapeutic innovation absolutely holds immense promise.

In another study just reported in the journal Science, German and Swiss scientists have developeda revolutionary technology, which enables mice and human retinas to detect infrared radiation. This ability could be useful for patients suffering from loss of photoreceptors and sight.

The researchers demonstrated this approach, inspired by the ability of snakes and bats to see heat, by endowing mice and postmortem human retinas with a protein that becomes active in response to heat. Infrared light is light emitted by warm objects that is beyond the visible spectrum.

The heat warms a specially engineered gold particle that the researchers introduced into the retina. This particle binds to the protein and helps it convert the heat signal into electrical signals that are then sent to the brain.

In the future, more research is needed to tweak the ability of the infrared sensitive proteins to different wave lengths of light that will also enhance the remaining vision.

This approach is still being tested in animals and in retinal tissue in the lab. But all approaches suggest that it might be possible to either restore, enhance or provide patients with forms of vision used by other species.

Hemant Khanna is an Associate Professor of Ophthalmology at the University of Massachusetts Medical School. His lab investigates molecular and cell biological bases of severe photoreceptor degenerative disorders, such as Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA). Find Hemant on Twitter @khannacilialab

A version of this article was originally published at the Conversation and has been republished here with permission. The Conversation can be found on Twitter @ConversationUS

Visit link:
Inherited blindness has a new cure, thanks to CRISPR - Genetic Literacy Project

The mosquitoes that carry zika, like Aedes aegypti, are considered by all but the most activist ecologists to be useless disease vectors. There is nothing they do in nature that isn't easily done by other mosquitoes and they can safely join the 99.999999999% of species that have gone extinct without causing a cascade of doom.

Seriously, Send me your hate mail, @ me on Twitter, try to cancel me, I don't care, that is absolutely correct. They are ecologically useless and have survived despite that, because evolution is not always fair.

After years of study across two different administrations, the EPA signed off on a plan that would allow release of genetically engineered mosquitoes that can't reproduce - since their range is limited their area of effect would be only what we want, like the Florida Keys. In the Los Angeles Times years earlier, I had debunked the claims of an anti-science Florida "Karen" who was convinced biologists didn't know what they were doing and we were all going to be dead, the environmental equivalent of that lawyer who filed a lawsuit claiming the Large Hadron Collider would create a black hole and swallow the planet. Lawyer-run groups that wrap themselves in the flag of environmentalism have also been raising money opposing natural control of mosquitoes recently, conspiratorially insisting Trump controlled every career scientist in government so it can't be science if an approval was made during his four years. They argue using the blanket denier-for-hire mantra; there could be unintended consequences.

Like what? The outcomes they invent are more magic than mosquito reality, such as that Frankenflies will escape and create mutant offspring. In science realty, male Aedes aegypti mosquitoes are harmless, they don't bite us. These time-limited males mate with females and simply can't have pestilence offspring.

A new study thinks it can fill the gap in the concern activists say they have.(1) What the scientists behind the paper use as their selling point is they won't have the "environmental complications" of GMO mosquitoes that can't reproduce, because by using CRISPR they have created mosquitoes that can't replicate the Zika virus at all, so females won't send it to humans when they bite.

Scientifically, that is great, but people with experience fighting the war on science know that it won't change anything. Science is a veneer for environmentalists. Activists hate CRISPR as much as they hate GMOs or RNAi or everything except the organic food created using Mutagenesis chemical and radiation baths. They will oppose this because the trait that keeps them from transmitting zika is heritable. It can be passed down. That will be spun into world-class "environmental complications" and Frankenbug unintended consequences so dumb even that terrible Dustin Hoffman movie Outbreak didn't try to use them.

If this gets close to testing, and the propaganda campaign against it ensues, the authors will then scramble to assure the public that Aedes aegypti proteins are not expressed salivary glands so humans are not at risk, this cannot mutate, etc., but they are not equipped to combat the disinformation and misinformation of a $2 billion-a-year marketing machine. By then half the public is already against it, the same way Democrats oppose the Keystone Pipeline despite Obama administration scientists clearing it - twice, the second time after Obama staffers made them do it again because they wanted to ban it.

That's a problem down the road, though. For now, applied use isn't even a discussion, it is just intriguing basic research on how we might solve an infectious disease problem in a way that might make people feel better than pesticides.

The problem is that environmentalists have turned all of biology into their new "Silent Spring" fundraisers. That's ironic, because Rachel Carson believed biological solutions like this were the ideal replacement for pesticides.

NOTES:

(1) Which falls into the real trap of activists; it is not about science, they claim you can fix the thing they object to but they will then move onto another. See Golden Rice. Academics believed that the concern was really about corporate control over food, and was not a war on science itself, so they created a public domain fortified bowl of rice. They quickly learned it was not about Monsanto at all. Having no corporate sponsor, they had no lawyers, but environmentalists are lawyer-heavy, and blocked its approval easily, while their marketing groups and academic allies insisted it would not work anyway.

Continue reading here:
An Alternate Approach To Stopping Mosquitoes That Spread Zika - Using CRISPR To Make Them Resistant To Carrying It - Science 2.0